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abstract
A bstract
Platelets are complex blood cells whose primary function is to participate in haemostasis, 
aggregating at the site of injury to obstruct blood flow out of the vessel. They are non-nucleated 
cells, derived by division of multinucleated bone marrow stem cells called megakaryocytes. 
Production of platelets is increased when the total circulating platelet mass declines, through the 
action of thrombopoietin and other stimulatory cytokines. Platelets contain a complex cytoskeleton 
and contractile protein network which enables shape change upon stimulation, active extrusion of 
the contents of storage granules and clot retraction. Platelets synthesise a number of factors which 
influence other platelets, the coagulation cascade, leukocytes and blood vessels. These are stored 
in granules and are extruded upon stimulation along a complex series of channels to reach the 
exterior. Platelet adhesion and aggregation begins with the binding of proteins to specific 
glycoprotein receptors in the platelet plasma membrane. Collagen, exposed at the site of damage 
to blood vessels is an important agonist in vivo, but other agonists are numerous and include 
substances released from activated platelets themselves, such as adenosine diphosphate (ADP) 
and serotonin, circulating substances such as adrenalin and vasopressin, products of the 
coagulation cascade such as thrombin, physical factors such as shear stress and stirring, and many 
foreign substances. The signal derived from the agonist binding is transferred across the plasma 
membrane to trigger a series of biochemical events which result in platelet shape change, 
fibrinogen binding, attachment of platelets in aggregates and secretion of granule contents, which 
recruit other platelets, and culminates with platelets losing their individual integrity to form a platelet 
mass. Platelet activity is constrained by the physical nature of the blood vessel wall and substances 
secreted by platelets and endothelial cells, as well as the rapid inactivation of free agonists.
Platelet enumeration is a routine part of a full blood count. Both manual methods, using a 
haemocytometer, and automated methods are available. Estimations of platelet number can be 
obtained by counting platelets seen in several microscope fields of the blood smear. Automated 
methods are more accurate than manual methods because of the larger number of cells counted. 
However, overlap of feline red cell and platelet size results in inaccuracies when aperture- 
impedance analysers are used. The presence of platelet aggregates in samples produces 
inaccuracies by all methods, because individual platelets within aggregates cannot be differentiated.
Anticoagulants are designed to inhibit blood coagulation and preserve cell morphology for 
haematological analysis. EDTA is the most frequently used anticoagulant; however, it causes 
platelet shape change and swelling and does not completely prevent activation or aggregation. In 
some individual human blood samples pseudothrombocytopenia and concurrent 
pseudoleukocytosis is seen when EDTA anticoagulant is used and this has been documented in 
other species. Other anticoagulants may also produce this effect. Citrate is not routinely used for 
anticoagulation for haematological analysis because of its dilutional effect.
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Because of the central role of platelets In haemostasis, changes in platelet number or function can 
have significant consequences. Immune-mediated thrombocytopenia is a rare disease in the cat in 
contrast to other species. More commonly, feline thrombocytopenia accompanies other diseases 
such as neoplasia, gastrointestinal disease and virus infection and may be a component of 
disseminated intravascular coagulation; however, resultant clinical signs of bleeding are not often 
seen. A variety of drugs and diseases may affect platelet function including renal disease, liver 
disease, dysproteinaemias, infectious diseases and disseminated intravascular coagulation. 
Hereditary platelet function disorders recognised in cats include Chediak-Higashi syndrome and 
von Willebrand's disease. Platelet neoplasia and thrombocythaemia is rare in cats; however 
thrombocytosis is not and may reflect physiological release from splenic and non-splenic pools or 
a reactive component of diseases, resulting in accelerated haematopoiesis, inflammatory 
diseases, some types of neoplasia or following splenectomy.
Difficulties in accurately enumerating feline platelets in the laboratory are well known; however, 
studies of the frequency of errors are lacking. A retrospective study was undertaken to examine 
the prevalence of low automated platelet counts compared with low blood smear-estimated 
platelet counts in feline blood samples over a twelve month period in the University of Glasgow 
Veterinary Haematology Laboratory. Platelet counts by means of an impedance counter (Minos® 
Vet, Abx Hematologie) were less than 200 x 109/l in 71% of samples and in 12% were less than 50 
x 109/l. However based on estimation of platelet numbers from smears, only 3.1% of samples had 
platelet counts less than 200 x 109/l, with 2.5% being less than 50 x 109/l. Four cats with blood 
smear-estimated thrombocytopenia had clinical signs of a bleeding disorder. Diseases associated 
with thrombocytopenia included neoplasia, cytotoxic chemotherapy and infectious diseases. There 
was no evidence that delay due to mailing of samples was associated with lower automated 
platelet counts than analysis on the day of sampling. The common occurrence of apparent 
thrombocytopenia in automated platelet counting was attributed to a combination of platelet 
aggregation, and the impedance method of cell type differentiation by size. It was concluded that 
vigilance and careful examination of blood smears is required to identify the few cats with true 
thrombocytopenia.
A further, prospective, study was then performed to determine if the use of an anticoagulant which 
inhibits platelet activity in human blood samples would reduce the difficulties in feline platelet 
enumeration associated with platelet aggregation. Blood samples from 51 cats were divided into 
aliquots and anticoagulated with EDTA, a citrate based anticoagulant containing the platelet 
inhibitors theophylline, adenosine and dipyridamole (CTAD) and, in 12 cases, citrate solution. Use 
of CTAD resulted in significantly higher (P < 0.001) platelet counts yielded by an impedance 
counter (Minos® Vet, Abx Hematologie), hemocytometer and smear estimation, than were 
obtained with EDTA. Subjective assessment of the degree of platelet aggregation on smears was 
significantly reduced (P < 0.001) in CTAD. Although often similar, automated and smear estimates 
of platelet counts were significantly higher (P < 0.05), and the degree of platelet aggregation
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significantly lower (P < 0.05) in CTAD than in citrate. This suggests that the platelet inhibitory 
activity of the CTAD, leading to reductions in platelet aggregation, was responsible for this effect. 
Automated total white cell counts in CTAD anticoagulated samples were significantly lower (P <
0.001) than automated counts in EDTA anticoagulated samples, and were similar to manual white 
cell counts in EDTA anticoagulated samples. Changes in both platelet and white cell counts in 
CTAD were clinically relevant. Mean platelet volume (MPV) and mean red cell volume (MCV) 
were significantly lower (P < 0.05) in CTAD than in EDTA. Although a statistically significant 
increase in red cell counts was seen with the use of CTAD compared with EDTA, the difference 
was not clinically relevant. No effect was seen on cell morphology or staining characteristics. It 
was concluded that the use of CTAD anticoagulant appears to offer advantages over either EDTA 
or citrate for feline haematology in avoiding pseudothrombocytopenia and pseudoleukocytosis.
Although CTAD had advantages over the use of EDTA for feline haematological analysis, a 
disadvantage is that it is a liquid and introduces a dilutional error. In addition, species differences 
in the response of platelets to antagonists, mean that it may not represent the optimal combination 
of platelet inhibitors for use in the cat. Alternatives such as a dry anticoagulant containing 
pyridoxal-5'-phosphate, which has shown promise in samples from human patients, may warrant 
investigation for use in feline samples. The use of specific techniques to evaluate the degree of 
platelet activation and aggregation may have advantages over the techniques used in this study in 
assessing the efficacy of a new anticoagulant for feline haematology. However, many of these 
techniques suffer from being technically difficult, requiring specialised equipment, requiring large 
volumes of blood for analysis or requiring sample handling which may itself induce activation or 
aggregation. The measurement of a new platelet parameter, mean platelet component 
concentration (MPC) by particular haematology analysers gives a useful assessment of platelet 
activation in unaggregated platelets, but is only suitable for use with samples collected in EDTA- 
based anticoagulants.
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preface
P reface
Because platelets are such a reactive cell, their study is fraught with technical difficulty. 
Nevertheless the study of platelet physiology and pathology has great importance in human 
medicine because of the common occurrence of vascular disease and thrombosis. Despite a great 
deal of research on platelets, many aspects of platelet function and the pathophysiology of platelet 
disease remain unknown. Aspects of platelet function and disease specific to many species are 
less well studied than in man. Platelet studies in the cat are complicated by the propensity for 
aggregation which is a feature of this species.
This study was prompted by the difficulties experienced in commercial haematology laboratories, in 
gaining an accurate platelet count in the cat, when sampling and sample handling were performed 
under routine clinical conditions using commonly available haematology equipment. Though this 
difficulty has been noted before, recommended methods to circumvent the problem, such as 
manual haemocytometer platelet counting, are time consuming for the commercial laboratory. It 
was also felt that these methods may not be entirely accurate in themselves.
The aims of this study are: to review the literature regarding platelet physiology and platelet 
disorders in the cat; to document the frequency of occurrence of inaccurate platelet counts in the 
commercial laboratories using standard procedures; and to investigate the usefulness of an 
alternative anticoagulant in preventing these difficulties.
The work was performed generous support of the Division of Small Animal Clinical Studies and the 
University of Glasgow Veterinary Haematology Laboratory, University of Glasgow Veterinary 
School, Bearsden Road, Glasgow, Scotland G61 1QH, and HemaTechnologies Ltd, Unit 13D/8 
Anniesland Village Business Park, Netherton Road, Glasgow, Scotland G13 1EU. The work formed 
part of a Clinical Scholarship in Small Animal Medicine at the University of Glasgow Veterinary 
School.
Thanks are due to my supervisor Professor Andrew Nash for his support and encouragement of the 
pursuit of the MVM, his great help with the thesis, and in facilitating the completion of the laboratory 
work; to Professor Roger Clampitt for the original idea and for numerous discussions and 
assistance with the research work itself; to Ronnie Barron and Kenny Williamson who gave their 
time and advice freely and happily and who performed much of the laboratory work as well as 
helping with the photography, teaching me about laboratory techniques and putting up with my 
endless questions; to the clinical staff of the Veterinary School, especially the nurses, who regarded 
the work as important and were of great assistance in the collection of samples; to Professor Stuart 
Reid for his advice about the study design and statistical analysis, and for imparting an enthusiasm
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for statistics; to Professor Max Murray for his enthusiasm and special encouragement in the early 
stages of the project, without which it may not have gone ahead; and to Professor David Bennett for 
his encouragement and practical support of the project.
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the function of platelets
1. P latelet  A natomy and  Ph ysio lo g y
1.1. O ver view  of the  Function  of  Platelets
Platelets are small non-nucleated cells which circulate in the peripheral blood and have an 
important role in haemostasis, acting in concert with vascular mechanisms and circulating 
coagulation factors. They accumulate at the site of vascular injury, binding to each other and to the 
injured endothelium to form a plug which restricts haemorrhage. Platelet adhesion to damaged 
endothelium is followed by aggregation with other platelets. Aggregation culminates in platelets 
losing their individual integrity and becoming enmeshed in fibrin which strengthens and stabilises 
the haemostatic plug against the force of reperfusion. Factors released from platelets contribute to 
the vasogenic response to haemorrhage (Kuter, 1991).
Activation of platelets occurs by exposure to a variety of stimulatory substances such as collagen 
and is amplified by release of factors from activated platelets themselves, endothelial cells, white 
blood cells and by products of the coagulation cascade. Exposure of binding sites for coagulation 
proteins during activation of the platelet leads to the formation of procoagulant complexes which 
accelerate the formation of thrombin.
Control of platelet activity is achieved by endothelial and circulating inhibitory factors and physical 
properties. Factors produced by endothelial cells which prevent adherence of platelets to normal 
endothelium and to each other, include prostacyclin (PGI2), endothelium-derived relaxing factor 
(EDRF), thrombomodulin and ADPase (Ware and Heistad, 1993). The negative surface charge of 
both platelets and endothelial cells results in mutual repulsion (Green and Thomas, 1995).
Platelets have additional functions unrelated to haemostasis. It has long been hypothesised that 
they promote the integrity of the vascular endothelium. Although there are numerous contradictory 
studies, the evidence suggests that the interactions of platelets and endothelial cells help to 
maintain the continuity and nonthrombogenicity of the vascular endothelium, but the mechanism 
remains poorly defined (Bithell, 1993a). Release of factors such as prostaglandins, collagenase, 
elastase, histamine, serotonin and chemotactins can initiate or contribute to the inflammatory 
response, however platelets have also been found to have some anti-inflammatory activity (Jain, 
1986a). Infliction of endothelial damage coupled with secretion by activated platelets of an 
endothelial growth factor which stimulates smooth muscle and fibroblast proliferation, is thought to 
play a role in the development of atherosclerosis in humans (Jain, 1986a).
Platelets also have the ability to phagocytose bacteria, bind endotoxin and they are thought to 
secrete p-lysin, a bactericidal serum protein (Jain, 1986a). Aggregation of bacteria with platelets
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may aid in their clearance from the circulation by the mononuclear phagocytic system (Jain, 1986a). 
However, detrimental consequences such as disseminated intravascular coagulation (DIC), 
formation of septic emboli, occlusion of blood vessels, vasculitis and haemorrhage due to 
thrombocytopenia may result from platelet-bacterial interactions during sepsis (Jain, 1986a). 
Aggregation of platelets around tumour cells may play a role in tumour metastasis, preventing rapid 
clearance of tumour cells from the circulation and allowing adherence and penetration of the 
vascular endothelium (Jain, 1993).
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1.2. T h ro m bo poiesis
Platelets are the final cell in a lineage that begins with a self-perpetuating progenitor cell and 
continues through megakaryoblasts, promegakaryocytes and megakaryocytes (Jain, 1986a) (Figure 
1.1). Megakaryocytopoiesis differs from erythropoiesis and granulocytopoiesis in that it involves 
successive divisions of nuclear material without nuclear or cytoplasmic division (termed 
endomitosis or nuclear endoreduplication), resulting in precursor cells with a polyploid nuclear DNA 
content of 4N, 8 N, 16N, 32N and sometimes 64N (Jain, 1986a). Cytoplasmic maturation occurs 
after completion of nuclear division (Bithell, 1993b). There is an increase in cytoplasmic volume 
(Jain, 1986a), formation of dense and alpha granules and production of platelet specific products 
such as platelet factor-4 (Kuter, 1991), von Willebrand factor (vWf), thrombospondin, p- 
thromboglobulin and the vWf receptor protein GPIb (Reagan and Rebar, 1995). Some substances 
such as fibrinogen are thought to be endocytosed into the cell (Reagan and Rebar, 1995). An 
extensive demarcation membrane system forms by deep invagination of the plasma membrane 
(Kuter, 1991) which has luminal openings to the cell surface (Jain, 1986a) and delineates the 
developing platelets (Burkitt et a/., 1993). The external surface of the demarcation membrane 
system becomes coated with glycoprotein which will form the glycocalyx of the mature platelet 
(Jain, 1986a).
The mechanism of platelet production from the megakaryocyte has been the subject of some 
controversy. Currently it is generally accepted that individual platelets are derived by the formation 
of “proplatelets” and their subsequent fragmentation at sites of demarcation (Jain, 1986a). This 
process has been observed both in vivo and in vitro (Choi et al.t 1996). Megakaryocytes lying in the 
subendothelial region of marrow sinusoids extend cytoplasmic projections called proplatelets into 
the sinusoid (Jain, 1986a), by rupturing the endothelial cell body (Bithell, 1993b). These proplatelet 
processes then extend into venous sinuses and begin to segment along the demarcation 
membranes, which then fragment and enter the circulation (Bithell, 1993b). This process is assisted 
by the platelet and megakaryocyte contractile proteins (Jain, 1986a). Large pieces of 
megakaryocyte and proplatelet processes may be found in the circulation as well as occasional 
megakaryocytes (Bithell, 1993b). The main site of thrombopoiesis is the bone marrow, however 
some megakaryocytes can be found in extramedullary locations such as lungs, spleen, liver, 
kidneys and heart (Jain, 1986a).
A mature megakaryocyte produces 2000-8000 platelets in a period of 3-12 hours, with the number 
being proportional to the cytoplasmic volume and ploidy value of the megakaryocyte (Jain, 1986a). 
Stimulation of thrombopoiesis causes release of platelets from megakaryocytes within 8  hours in 
humans, and is accompanied by an increase in the average ploidy of the megakaryocytes in the 
bone marrow within 2 days, and an increase in megakaryocyte numbers within 3-5 days (Kuter, 
1991). A cohort of larger platelets enters the circulation increasing mean platelet size temporarily, 
with mean platelet size returning to normal before maximal changes in precursor megakaryocytes
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(Bithell, 1993b). Inhibition of thrombopoiesis is accompanied by a decrease in ploidy of 
megakaryocytes in the bone marrow (Kuter, 1991).
The early stages of megakaryocytopoiesis are stimulated by several cytokines that also stimulate 
other haemopoietic lineages including: interleukin-3 (IL-3); granulocyte-macrophage (GM)-CSF; c- 
kit ligand (KL, also called stem cell factor and steel factor) (Kaushansky, 1997). A theoretical late- 
acting lineage-specific hormone for platelet production was named thrombopoietin in the 1950’s 
(Kaushansky, 1997). A range of physiological properties was predicted based on experimental 
findings which showed that plasma from thrombocytopenic animals increased thrombopoiesis in 
vitro and in vivo and plasma from thrombocytotic animals inhibited thrombopoiesis (Kuter, 1991). 
These properties are listed in Table 1.1.
• Plasma concentration inversely proportional to platelet mass or numbers
• Causes differentiation of megakaryocyte lineage
• Has no effect on megakaryocyte progenitor cell proliferation
• Increases megakaryocyte size, ploidy and expression of membrane 
glycoproteins
• Specific to platelet lineage
Table 1.1 The predicted properties of thrombopoietin (Kaushansky, 1997)
Recently in the course of murine leukaemia research a protooncogene (c-mpl) was identified which 
was found to be a member of the haemopoietic cytokine receptor family. This receptor was found in 
megakaryocytes and their precursors and neoplastic cell lines exhibiting features of 
megakaryocytes. Purification and study of the receptor ligand (termed Mpl ligand (ML)) has shown it 
to have nearly all of the predicted properties of thrombopoietin, but also some unexpected 
properties (Table 1.2) (Kaushansky, 1997). It is likely to be the primary regulator of platelet 
production (Boudreaux, 1996).
• ML plasma concentration is inversely proportional to platelet counts in humans 
(with some exceptions)
• Administration of ML to animals increases platelet counts for the duration of 
treatment
• Increases megakaryocyte size, ploidy and expression of membrane 
glycoproteins
• ML-induced megakaryocytes have been shown to produce functional platelets
• Induces proliferation of megakaryocyte progenitor cells
• Supports the proliferation of many haemopoietic progenitor cells in combination 
with other cytokines
Table 1.2 Properties of Mpl Ligand (ML) (Kaushansky, 1997)
The site of thrombopoietin formation remains unknown. There is some evidence that the kidney is a 
source of thrombopoietin or its precursors (Jain, 1986a; Bithell, 1993b). However the expression of 
thrombopoietin mRNA by several different types of endothelial cells and fibroblasts suggests that 
the distribution of production may be widespread (Boudreaux, 1996). Platelet mass may be more 
important than platelet number in regulating thrombopoiesis (Bithell, 1993b; Reagan and Rebar,
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1995) however the evidence is inconsistent and the “detector” mechanisms for recognition of 
platelet mass or number remain undefined (Bithell, 1993b). It has been proposed that 
thrombopoietin production is constant but its uptake by platelets or megakaryocytes in proportion to 
their total mass results in inversely proportional circulating concentrations (Boudreaux, 1996). 
Another theory involves regulation of gene expression by a negative feedback mechanism provided 
by either platelets or megakaryocytes (Boudreaux, 1996). There is also some evidence to suggest 
the presence of a thrombopoietic inhibitory factor derived from the spleen (Jain, 1986a; Bithell, 
1993b).
About 30-40% of the total platelet mass in humans, dogs and rabbits is sequestered in the spleen 
and can be rapidly mobilised with adrenalin administration (Jain, 1986a). The splenic pool contains 
a high proportion of large young platelets (Jain, 1986a; Bithell, 1993b). This splenic pool is not 
present in all species (for example ponies). Another rapidly mobilisable non-splenic pool of 
sequestered platelets is released during exercise in dogs and rabbits but does not contain a high 
proportion of large platelets (Jain, 1986a; Bithell, 1993b). The location of this pool is not yet known, 
although it is hypothesised to be the lung, and its functional importance is questioned (Bithell, 
1993b).
Circulating platelet lifespan ranges from 5 to 10 days in most species (Jain, 1986a), but is much 
shorter, with a mean of 31 hours in the cat (Reagan and Rebar, 1995). Platelets are cleared by the 
mononuclear phagocytic system, principally in the spleen (Bithell, 1993b), with liver, heart and bone 
marrow being additional important sites of clearance in humans and dogs (Jain, 1986a). Whether 
platelets are removed in an age dependent or random manner remains controversial (Bithell, 
1993b). Difficulties in labelling techniques, such as impairment of platelet function or preferential 
labelling of large platelets, have delayed a definitive answer, and conflicting results to date may also 
reflect species differences (Bithell, 1993b). The currently prevailing view is that in man, senescence 
predominates, with random destruction being more important in populations of older platelets 
(Bithell, 1993b).
Another unresolved issue is the origin of platelet size heterogeneity. Although some studies have 
shown that large platelets are the youngest platelets and that platelets become smaller and less 
active with age, other evidence of cohorts of different sized platelets which remain the same size 
throughout their lifespan, is contradictory (Bithell, 1993b). Existing evidence implies that larger, 
older megakaryocytes release small platelets and smaller, younger megakaryocytes release large 
platelets (Bithell, 1993b). This may account for the finding of increased proportions of large platelets 
in conditions of increased thrombopoiesis (Bithell, 1993b).
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1.3. P latelet  Structure
Feline platelets are larger than those of other species, with a mean volume of 11.0-18.1 fL (Weiser 
and Kociba, 1984), compared with platelet volumes in the dog, pig and human of 7.6-8.3 fL and in 
the ox, horse, sheep, rat, guinea pig and mouse of 3.2-5.4 fL (Jain, 1986a). Within an individual 
animal larger platelets have a greater number of granules, a greater capacity for protein synthesis 
and a greater amount of many secretory products than smaller platelets and hence are thought to 
be functionally more active (Jain, 1986a; Bithell, 1993b). Whether the larger size of feline platelets 
contributes to their propensity to aggregate in vitro and for the predisposition to thrombosis in cats 
is not clear.
Platelet numbers appear to be inversely proportional to platelet size within healthy human 
individuals, but the relationship is nonlinear (Bessman et at, 1981). The change in platelet size is 
greatest in the lower range of platelet counts (Bessman et at, 1981). However despite having 
significantly higher MPVs, a group of 10 Cavalier King Charles Spaniels did not have significantly 
different manual platelet counts to dogs of other breeds in one study (although automated counts 
were significantly different) (Brown et at, 1994). Nakeff and Ingram (1970) presented evidence that 
the relationship between MPV and platelet count is maintained between species, showing that 
mean platelet volume decreased as the mean platelet count for the species increased, in humans, 
dogs, rats and mice (see Table 1.3). However, comparison of published reference ranges for size 
and volume of platelets for a range of species does not appear to reflect this (Table 1.3). Variations 
in techniques used to determine platelet indices and the dependency of mean platelet volume on 
platelet number within individuals in a species complicate interpretation of this data.
On stained blood smears feline platelets appear as small pale blue discoid cells with a central 
cluster of purple granules (Jain, 1986a). They may range in size up to the size of red blood cells 
(Jain, 1993) and may be clumped together ranging from small groups to large amorphous masses.
Platelets are non-nucleated cells with a complex ultrastructure that can be divided into four 
functional zones (Jain, 1986a) (Figure 1.2). The peripheral zone consists of the plasma membrane 
and an outer glycocalyx. The plasma membrane has a phospholipid bilayer structure in common 
with other cells (Tuffin, 1991). It is punctuated with orifices which are the openings of the open 
canalicular system (Bithell, 1993b). On the exterior of the plasma membrane is a the thick 
filamentous glycocalyx, rich in mucopolysaccharides, and containing several types of glycoprotein 
receptor which play an important role in platelet adhesion, aggregation and signaling (Jain, 1986a; 
Tuffin, 1991). The plasma membrane differs from that of other cells in that the number of 
membrane proteins exposed to the external surface is twice as great as the number facing inwards 
(Burkitt ef at, 1993).
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Species Platelet count * (x 103/|jL)
Mean platelet 
volume (fL)
mouse 160-410* 
>1 0 0 0 f 
1302 ± 44§
3.3*
32-5.4* 
4.02 ± 0.13§
rabbit 250-270* 3.3*
sheep 300-600*
250-750t
4.4*
3.2-5.4*
guinea pig 250-850* 4.5*
3.2-5.4*
rat 500-1300* 
847 ± 36§
4.7*
3.2-5.4* 
5.37 ± 0.09§
ox 100-800*
100-800*
5.0*
3.2-5.4*
horse 120-360*
100-350*
5.1*
3.2-5.4f
human 200-400* 
198±14s
6.7*
7.6-8.3+ 
7.74 ± 0.22§
pig 350-700*
100-900*
6.9* 
7.6-8.3f
dog 200-900* 
200-500* 
380 ± 47s
7.5*
7.6-8.3f 
7.17 ± 0.33§
cat 300-700*
300-800*
296-850#
1 2 .0 * 
15.1f 
11.0-18.1#
Table 1.3 Comparison of platelet number and volume of various mammalian species as published 
by* (Poole, 1996), t (Jain, 1993) and § (Nakeff and Ingram, 1970), and * (Weiser and Kociba, 1984).
* range or mean ± sd
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The sol-gel zone consists of the platelet cytoplasm which contains a well developed microfilament 
and microtubule cytoskeleton. There is a circumferential band of microtubules located around the 
cell periphery and the cytoplasm is rich in contractile proteins, mainly actin, and other filamentous 
elements (Tuffin, 1991; Burkitt et al.t 1993). These structural proteins help maintain platelet shape, 
but also enable shape change, pseudopod formation and clot retraction (Jain, 1986a) and probably 
have a role in extrusion of granule contents (Burkitt et al., 1993).
The organelle zone comprises the other platelet organelles. Platelets retain the enzyme systems for 
anaerobic and aerobic respiration and contain a few mitochondria and glycogen granules (Burkitt et 
al., 1993). In some platelets Golgi elements and ribosomes are seen (Jain, 1986a; Burkitt et al., 
1993). However, the most conspicuous organelles, occupying about 20% of platelet volume, are the 
four types of electron dense granules (Burkitt et al., 1993). Alpha granules vary in size and contain 
several polypeptides such as platelet factor 4; p-thromboglobulin; coagulation factors fibrinogen, 
factor V and factor Vlll/vWf; platelet-derived growth factor; fibronectin; thrombospondin; and other 
growth factors (Burkitt et al., 1993). Dense bodies or dense granules are very electron dense 
(Burkitt et al., 1993) and contain adenosine triphosphate (ATP) and diphosphate (ADP), Ca2+ and 
serotonin (McNicol et al., 1993). Lysosomes containing hydrolytic enzymes (McNicol et al., 1993) 
and peroxisomes containing catalase are few in number (McNicol et al., 1993).
Lastly, platelets contain two membrane systems. The plasma membrane-derived open canalicular 
system is an intercommunicating system of channels which open on the platelet surface (Jain, 
1986a) and are associated with the cytoskeleton (Burkitt et al., 1993). They provide a passage for 
secretion and internalization of substances (Jain, 1986a). The dense tubular system is found just 
under the circumferential band of microtubules and contains a platelet specific peroxidase (Burkitt 
et al., 1993). It is the site of prostaglandin synthesis and calcium sequestration within the platelet 
(Jain, 1986a).
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glycocalyx
plasma
membrane
open canalicular 
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alpha granule
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dense body
dense tubular 
system
microtubules
Figure 1.2 Ultrastructure of platelets as seen on electron micrographs (drawing modified by author 
based on (Bithell, 1993b)
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1.3.1. Platelet membrane adhesive proteins
Platelet adhesion and aggregation begin with the binding of adhesive proteins to glycoprotein 
receptors in the platelet plasma membrane-glycocalyx complex. Many of these receptors belong to 
the integrin family: heterodimeric molecules composed of alpha and beta subunits which are found 
on virtually all cells. Unique combinations of subunits lead to specificity of the receptor for particular 
ligands. The nomenclature of integrins has recently changed to reflect their subunit structure 
(McNicol et al., 1993; Lefkovits et al., 1995). Previously, naming of platelet membrane adhesive 
proteins was based on the electrophoretic bands formed by glycoproteins of differing molecular 
weight, with sub-bands being recognised as improved gel systems allowed further discrimination 
(Plow and Ginsberg, 1991). Whilst the integrin group make up some of these glycoproteins, two 
non-integrin platelet adhesive glycoproteins are glycoprotein lb and glycoprotein IV (Lefkovits et al., 
1995). There are species differences in the properties and relative abundance of each glycoprotein 
band (McNicol etal., 1993). Feline platelets lack the glycoprotein I band (Nurden etal., 1977).
The major platelet adhesive proteins are as follows:
• <xiibp3 integrin (glycoprotein llb/llla) contains the fibrinogen binding sites critical to platelet 
aggregation but also has a secondary role in platelet adhesion (Lefkovits et al., 1995). There is 
more than one binding site for different parts of the fibrinogen molecule. When platelets are 
activated, a conformational change occurs in the anbp3 complex to permit fibrinogen binding at 
these sites. Once fibrinogen binds, additional changes including receptor clustering occur to 
permit and promote platelet aggregation (McNicol et al., 1993). This receptor also binds 
fibronectin, vWf, and vitronectin (Lefkovits etal., 1995).
• glycoprotein lb (nonintegrin) is the principal receptor involved with initial contact between 
platelets and the vessel wall (Lefkovits et al., 1995). It exists in a complex with glycoprotein IX 
and glycoprotein V on the platelet surface and binds vWf (Lefkovits et al., 1995). Its cytoplasmic 
domain is linked to the actin cytoskeleton and this association may be important in maintenance 
of cell shape and vWf binding (McNicol et al., 1993). The glycoprotein Ibp subunit is 
phosphorylated following exposure to agents that increase intracellular concentrations of cyclic 
adenosine monophosphate (cAMP) and may be responsible for keeping platelets in a resting 
state (McNicol etal., 1993).
• a2Pi integrin (glycoprotein la/lla) is a collagen receptor which mediates platelet-collagen 
adhesion (Lefkovits et al., 1995).This appears to be the principal receptor for collagen (Lefkovits 
etal., 1995).
• OvP3 integrin is a receptor for vitronectin, fibrinogen, fibronectin and vWf which mediates platelet 
adhesion (Lefkovits etal., 1995).
• 015P1 integrin (glycoprotein Ic/lla) is a fibronectin receptor which mediates platelet adhesion 
(Lefkovits et al., 1995). It is also called a2ps by some authors (McNicol et al., 1993).
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• aePi integrin is the laminin receptor and may be important for platelet adhesion (Lefkovits et a/., 
1995). It is also called a2P6 in some references (McNicol et at., 1993).
• glycoprotein IV (nonintegrin) in a receptor for collagen and thrombospondin (Lefkovits et at., 
1995).
1.3.2. Platelet factors
Substances involved with coagulation that are associated with platelets are designated platelet
factors (PF) 1 to 10; however, all except PF-2, PF-3 and PF-4 are rarely used terms.
• PF-1 is plasma coagulation factor V (Bithell, 1993b).
• PF-2 is fibrinogen activating factor. This is a globulin unique to platelets which may have a 
proteolytic action on fibrinogen but its physiologic role is still undetermined. (Bithell, 1993b). In 
vitro, it inhibits antithrombin III, induces aggregation and accelerates the rate of thrombin- 
fibrinogen reaction (Bithell, 1993b).
• PF-3. This thermostable lipoprotein is probably the platelet plasma membrane in an activated or 
available state (Bithell, 1993b). PF-3 activity is also present in phospholipid derived from 
erythrocytes, leukocytes and most tissues (Bithell, 1993b; Bithell, 1993c). When coagulation is 
activated by the extrinsic pathway PF-3 activity is provided by tissue factor (Bithell, 1993c). PF-3 
serves to bind and orient coagulation factors to form active complexes. The plasma membrane 
of activated platelets provides the optimum charge mosaic of phospholipids for this purpose 
explaining the greater coagulant activity of platelet membranes compared to platelet substitutes 
(Bithell, 1993b; Bithell, 1993c). PF-3 is required for activation of factor X and the formation of 
prothrombinase (Bithell, 1993b). Formation of a complex of calcium, PF-3, factor Vlll’ and factor 
IXa results in formation of an enzyme capable of activation of factor X (Bithell, 1993c). A 
complex formed from PF-3, factor V or factor V’, factor Xa and calcium is termed 
prothrombinase and leads to the conversion of prothrombin to active thrombin (Bithell, 1993c). 
Prothrombinase involves PF-3 that is made available following platelet aggregation and release 
(Bithell, 1993b).
• PF-4. This glycoprotein is stored in a-granules and only traces are found in plasma (Bithell,
1993b). PF-4 combines with and inactivates the anticoagulant heparin (Bithell, 1993b). It also
facilitates platelet aggregation (Bithell, 1993b).
• PF-5 refers to platelet fibrinogen (Bithell, 1993b).
• PF- 6  refers to platelet-associated plasmin inhibitor (Bithell, 1993b).
• PF-7 is cothromboplastin (Bithell, 1993b).
• PF- 8  is antithromboplastin (Bithell, 1993b).
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• PF-9 is accelerator globulin stabilising factor (Bithell, 1993b).
The nature and physiological importance of platelet factors 7, 8 and 9 have yet to be elucidated 
(Bithell, 1993b).
• PF-10 is serotonin and its functions include vasoconstriction and enhancement of platelet 
aggregation (Jain, 1986a)
1.3.3. Other platelet proteins
B-thromboalobulin is a low affinity antiheparin protein very close in structure to PF-4 and may be 
derived from the same precursor molecule (Bithell, 1993b). It is stored in a-granules and upon 
release binds to endothelial cell membranes, where it inhibits prostacyclin formation (Bithell, 
1993b). It may be involved in the pathogenesis of thrombosis (Bithell, 1993b).
Platelet derived growth factor (PDGF) is an important serum mitogenic factor, stimulating growth of 
endothelial cells, smooth muscle cells, glial cells and fibroblasts, and is also chemotactic for 
fibroblasts (Bithell, 1993b).
Thrombospondin. This glycoprotein is also known as thrombin-sensitive protein, the endogenous 
“lectin” of platelets, and glycoprotein G (Bithell, 1993b). It is stored in a-granules and secreted by 
platelets but also produced by endothelial cells, monocytes and macrophages, smooth muscle cells 
and fibroblasts (Bithell, 1993b). It binds to the surface glycolipids of activated platelets and is 
apparently involved with platelet aggregation, fibrin formation and platelet induced 
haemagglutination (Bithell, 1993b).
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1.4. Platelet  A dhesion
Attachment of platelets to nonplatelet surfaces is the first step in blood coagulation (Bithell, 1993a). 
Platelets do not adhere to endothelial cells themselves. The main site of attachment is collagen 
fibres deep in the subendothelial layers, but platelets may also adhere to elastic fibres and other 
non-collagenous substances in interactions that require free calcium (Bithell, 1993a). Platelet 
adhesion to collagen proceeds in the absence of free calcium and involves specific receptors on the 
platelet and the collagen, vWf and possibly other “adhesive” proteins (Bithell, 1993a). Physical 
factors such as rate of blood flow, velocity gradient and red cell concentration also appear to affect 
platelet adhesion (Bithell, 1993a). In blood vessels such as capillaries in which there is a high shear 
rate, platelet adhesion increases as PCV rises through a wide range, presumably because 
increasing numbers of red cells deflect platelets laterally, resulting in increased vessel wall contact 
(Moore, 1991). The effect of increasing PCV is not as marked in large veins (Moore, 1991).
von Willebrand’s factor is a large multimeric molecule composed of many dimeric protomers 
(Bithell, 1993c). It circulates as a complex with factor VIII, in which the larger vWf acts as a carrier 
molecule for factor VIII (Bithell, 1993c). It is produced by endothelial cells and megakaryocytes and 
is present in plasma, on endothelial surfaces, on platelet membranes, and secreted from storage 
granules by activated platelets (Bithell, 1993c). In cats, a higher percentage (25%) of vWf is 
expressed in platelets than in dogs (Waters et al., 1989). Large vWf multimers are stored in 
endothelial cells (Weibel-Palade bodies) and secreted under appropriate stimulation (Bithell, 
1993c). Adrenalin, vasopressin, exercise and venous occlusion can all stimulate vWf release 
(Moore, 1991). Circulating vWf is heterogeneous. Platelet vWf consists of larger multimers than 
plasma vWf. It may be cleaved by circulating calcium activated proteases (Bithell, 1993c).
There is more than one platelet receptor for vWf and it has been shown that dimeric vWf first binds 
to platelet membrane glycoprotein lb and subsequently to glycoprotein llb-llla on the activated 
platelets (Bithell, 1993a). vWf secreted by platelets binds preferentially to the glycoprotein llb-llla 
receptor (Bithell, 1993a). Collagen adhesion may preferentially involve larger multimers (Bithell, 
1993a).
Fibronectin is another adhesive protein which is synthesised by endothelial cells and present in 
plasma, connective tissue and platelet granules (Bithell, 1993a). Activated platelets have receptors 
for fibronectin, which may act as a collagen receptor when bound to platelets and may assist in vWf 
mediated adhesion but is unlikely to be a major factor in platelet adhesion (Bithell, 1993a).
Platelets may also adhere indirectly to the vascular wall by adhering to leukocytes bound to the 
endothelium (Ware and Heistad, 1993).
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1.5. Platelet  A ctivation
Platelet activation begins with the interaction of agonists with platelet receptors #. The signal derived 
from attachment of the agonist is then transferred across the plasma membrane to trigger a series 
of biochemical changes within the platelet via G proteins on the internal membrane surface 
(McNicol et a/., 1993). These biochemical changes lead to a change in cell shape with extension of 
projections called pseudopods, binding of fibrinogen to the platelet surface, attachment of platelets 
in aggregates and secretion of platelet granule constituents (McNicol et al., 1993). At the same time 
as platelets are activated to form a platelet plug, rearrangement of membrane phospholipids and 
microvesicle sprouting from the platelet surface promotes blood coagulation (McNicol et al., 1993). 
Following secretion of granule contents (the release reaction) the platelets begin to lose their 
individual integrity (Gentry and Downie, 1993). A fibrin mesh is formed which stabilises the platelet 
plug, first around the periphery of the platelet aggregates and then throughout the platelet plug 
(Gentry and Downie, 1993; Bithell, 1993a) (Figure 1.3).
1.5.1. Agonist Interaction with membrane receptors
A variety of agents have been shown to activate platelets including collagen, thrombin, vWf, 
fibrinogen, adrenalin, vasopressin, ADP, thromboxane A2 , PAF and serotonin (Brass, 1991; 
McNicol et al., 1993). The response to various agonists differs, for example collagen and thrombin 
initiate granule secretion (and are therefore known as strong agonists) whereas ADP and adrenalin 
are weak agonists (Brass, 1991). Species differences exist in the responses to various agonists 
(Table 1.4); however, all animal platelets respond to thrombin and collagen by undergoing shape 
change, irreversible aggregation and release of dense granule contents (Poole, 1996). Feline 
platelets differ from those of other domesticated species in that serotonin is a strong platelet agonist 
(Poole, 1996) and low concentrations of ADP can act as a strong agonist (MacMillan and Sim, 
1970). Specific receptors have been isolated for many of these agonists (McNicol et al., 1993). The 
extracytosolic aspect of these transmembrane proteins forms the agonist binding site. Agents such 
as adenosine, prostacyclin (PGI2) and PGD2, can inhibit platelet activation by acting on specific 
receptors (McNicol eta!., 1993).
The cytosolic aspect of the transmembrane receptor proteins is linked to guanine nucleotide- 
binding proteins (G proteins). There are two broad categories of G proteins: high molecular weight 
heterotrimeric G proteins and low molecular weight G proteins (McNicol et al., 1993). The family of 
heterotrimeric G proteins play a regulatory role in the signal transduction pathways of many cell
* Platelets subjected to elevated levels of fluid shear stress will aggregate in the absence of exogenous 
agonists. The mechanism involves binding of vW f to glycoprotein lb which leads to opening of plasma 
membrane Ca channels, resulting in an influx of extracellular Ca. (Chow et al. 1992)
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types, mediating the interaction of the receptor to the intracellular effector pathway. Individual G 
proteins either stimulate or inhibit the effector (Brass, 1991). The recently recognised low molecular 
weight G proteins also appear to have a role in signal transduction in platelets and some may be 
involved in secretion of a-granule contents (McNicol etal., 1993).
Species PAF AA serotonin ADP ATP adrenalin
Human Ir Ir R Ir Ant Var
Mouse X Ir Ir P
Rabbit Ir Ir R R Ant P
Dog Var Ir/R Ir Ant Var (Ir, P)
Cat Ir Ir Ir Ir, P
Sheep P Ir X
Cattle Ir SC P Ir X
Horse Ir R R Ir X
Table 1.4 Effect of common agonists on platelets of different species (Poole, 1996).
Ir = irreversible aggregation, R = reversible aggregation, Ant = antagonist of ADP response, 
Var = variable response, X - n o  effect, P = potentiatory action only, SC = shape change only
1.5.2. Activation of cytosolic second messenger pathways
At least three effector molecules are present in the platelet cytoplasm: phospholipase C 
(phosphoinositide pathway), phospholipase A2 (eicosanoid or arachidonate pathway) and adenyl 
cyclase (cAMP pathway) (Brass, 1991).
1.5.2.1. Activation of phospholipase C
Phospholipase C activation by G proteins occurs when agonists such as thrombin, serotonin, 
vasopressin, PAF and thromboxane A2 bind to transmembrane receptors (McNicol et al., 1993). 
Several types of this enzyme have been identified (McNicol et al., 1993). Phospholipase C cleaves 
phosphatidyiinositol biphosphate to form inositol 1,4,5-triphosphate and diglyceride (McNicol et al.,
1993).
phosphatidyiinositol biphosphate —phol,,holip," c-^ inositol 1,4,5-triphosphate + diglyceride
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Inositol 1,4,5-triphosphate interacts with a receptor on the dense tubular system to release calcium 
causing a rise in cytosolic calcium concentration (McNicol et al., 1993).
Diglyceride activates protein kinase C (Brass, 1991). Protein kinase C transfers a phosphate group 
from ATP to a number of platelet proteins leading to pseudopod formation, granule membrane 
fusion and platelet aggregation (associated with fibrinogen binding) (McNicol et al., 1993). Protein 
kinase C has also been implicated in platelet secretion (McNicol et al., 1993).
Q  platelet agonist
membrane receptor 
J dense granule 
alpha granule unstimulatedllb/llla
platelet
Ib/IX activationla/lla
, vWf, TSP
aggregation
ADP, calcium secretion
llb/llla
la/lla Ib/IX procoagulant
activityadhesion
subendothelia! matrix 
(collagen; vWf)
stimulated
platelet
= fibrinogen, TSP = thrombospondin
Figure 1.3 Diagram of platelet activation (Howard and Hamilton, 1997).
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1.5.2.2. Activation of phospholipase A2
The eicosanoid or arachidonate pathway leads to the synthesis of thromboxane A2 (TXA2). Since 
thromboxane is a platelet agonist this provides a positive feedback loop enabling full platelet 
activation by agonists such as collagen and adrenalin (McNicol et al., 1993). The arachidonate 
pathway is well developed in feline, rabbit and human platelets but is rudimentary in equine and 
bovine platelets (Poole, 1996).
platelet phospholipase A2 —> arachidonic cyclooxygenase thromboxane synthetase —> thromboxane
phospholipids acid
Phospholipase A2 is activated in the presence of increased cytosolic calcium concentrations (Brass, 
1991) but the mechanisms of regulation of its activity are still not fully understood (McNicol et al.,
1993). The intracellular availability of arachidonic acid also regulates TXA2 production (McNicol et 
al., 1993) and this may be modified by diet in the cat for whom it is an essential fatty acid.
1.5.2.3. Adenyl cyclase
Receptors for adenosine, PGI2 and PGD2 are linked via a G protein to the activation of adenyl 
cyclase (Scrutton and Athayde, 1991; Bithell, 1993a). This enzyme catalyses the synthesis of 
cAMP, an inhibitor of platelet function, from ATP (Bithell, 1993a). At least two phosphodiesterases 
in the cytosol degrade cAMP to AMP and it is the balance of this enzyme activity which determines 
the concentration of cAMP which in the cytosol (Bithell, 1993a). Thus phosphodiesterase inhibitors, 
such as theophylline and dipyridamole, also lead to increased cAMP concentrations (Bithell, 1993a). 
Inhibitors of adenyl cyclase include adrenalin, serotonin, thrombin, collagen and PAF (Bithell, 
1993a).
Cyclic AMP inhibits shape change and aggregation but its mechanism of action is unclear (Bithell, 
1993a). It may act by maintaining the non-active phosphorylated state of various cytosolic proteins 
including protein kinases and the enzymes phospholamban and thrombolamban which stimulate 
the calcium pump in the dense tubules (Bithell, 1993a).
Activation of platelet guanyl cyclase by nitric oxide donors such as endothelium-derived relaxing 
factor (EDRF) leads to elevations in cGMP and inhibition platelet function (Scrutton and Athayde, 
1991; Butt and Walter, 1996). When stimulated by other agonists, however, cGMP appears to have 
excitatory effects on platelets and the details of cGMP activity and its relation to cAMP activity are 
still poorly understood (Scrutton and Athayde, 1991).
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1.5.3. Increased intracytoplasmic calcium concentration
Calcium concentrations in the cytosol of resting platelets are maintained at a low level by a 
combination of several mechanisms including the limited permeability of the plasma membrane to 
calcium and the presence of transmembrane calcium pumps which move calcium from the cytosol 
into the dense tubular system where it is stored, or out of the cell (Brass, 1991).
Upon activation, cytosolic calcium concentrations rise by influx of calcium from the extracellular fluid 
and from the dense tubular system (Brass, 1991). Inositol 1,4,5-triphosphate interacts with a 
receptor on the dense tubular system to cause calcium outflow via a Ca Mg-ATPase pump (Brass, 
1991). Influx across the plasma membrane is induced by some agonists such as ADP but the 
mechanisms are poorly understood at present (Sage, 1996).
The rise in cytosolic calcium is central to platelet activation, leading to shape change, aggregation 
and secretion of granule contents (Sage, 1996), by activation of calcium-dependent enzymes such 
as phospholipase A, phospholipase C, myosin light-chain kinase and many others (Brass, 1991).
1.5.4. Shape change
On activation, the shape of platelets changes from discoid to more spherical with long and short 
cytoplasmic extensions or pseudopods (Tuffin, 1991). Shape change is largely due to 
reorganisation of the cytoskeletal actin filamentous network (Tuffin, 1991) triggered by activation of 
protein kinase C and/or a rise in cytoplasmic calcium (McNicol et al., 1993). The proportion of 
filamentous actin increases through polymerisation of actin monomers by mechanisms which are 
not yet fully elucidated (Tuffin, 1991). Concurrent myosin phosphorylation by myosin light-chain 
kinase and protein kinase C and then association with actin provides the contractile unit which is 
anchored to the plasma membrane by attachment (through actin-binding protein) to the glycoprotein 
Ib/IX complex (Brass, 1991). Contraction of the actin and myosin cytoskeleton also results in 
centralisation of granules prior to release of their contents (McNicol et al., 1993).
1.5.5. Platelet fibrinogen binding and aggregation
Aggregation of platelets occurs when fibrinogen bridges the glycoprotein llb/llla receptors on 
adjacent platelets (Figure 1.4). Although it is clear that the glycoprotein llb/llla (nbP3) complex on the 
platelet surface is the binding site for fibrinogen, several aspects of the mechanism are not fully 
understood. Fibrinogen binding sites are unavailable in unstimulated platelets, but activation results 
in a calcium dependent conformational change in the glycoprotein llb/llla complex which exposes 
the fibrinogen binding site (Tuffin, 1991). After binding of fibrinogen, clustering of glycoprotein
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llb/llla receptors occurs, and it is proposed that this facilitates anchoring of cytoskeletal proteins to 
the plasma membrane (Tuffin, 1991). The binding of fibrinogen to human platelets is initially 
reversible, becoming irreversible upon release of granule constituents (Tuffin, 1991) (Figure 1.4).
Figure 1.4 Diagram of platelet-fibrinogen binding to form aggregates (Lefkovits et al, 1995)
1.5.6. Secretion of platelet granule constituents (release reaction)
Platelet granules are moved to the centre of the platelet by the action of the microtubule and 
microfilament cytoskeleton (Bithell, 1993a). This process is regulated through calcium, calmodulin 
and myosin light chain kinase (McNicol et al., 1993). The platelet granule membranes then fuse 
with the membranes of the open canalicular system resulting in extrusion of their contents to the 
external environment (Bithell, 1993a). Membrane fusion is driven by a protein kinase C - mediated 
process which may involve the intracellular synthesis of histamine (McNicol et al, 1993). The 
contents of dense bodies are secreted first and a-granule contents secreted later, with stronger 
stimulus. Lysosomal enzyme secretion requires still stronger stimuli (Bitheil, 1993a). The release of 
the aggregatory granule contents recruits other platelets and is required for the formation of large 
irreversible platelet aggregates and the formation of the insoluble fibrin network (Gentry and 
Downie, 1993).
resting platelet
G P  llb/llla receptors in 
ligand-unreceptive state
platelet agonist
fibrinogen
activated platelet 
G P  llb/llla receptors in 
ligand-receptive state
aggregating platelets
GP llb/llla receptors occupied by 
fibrinogen, which forms bridges 
between adjacent platelets
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1.5.7. Procoagulant response
During activation the platelet surface develops significant procoagulant activity which accelerates 
the coagulation cascade (Michelson and Shattil, 1996). There is movement of plasma membrane 
phospholipids from the inner layer to the outer surface of the plasma membrane, shedding of 
microparticles from the membrane surface and an increase in the number of binding sites for factor 
Va and factor Villa on both the plasma membrane and microparticle surface (Michelson and Shattil, 
1996).
1.5.8. Clot retraction
Clot retraction is dependent on the presence of platelets, becoming slow and deficient in severe 
thrombocytopenia (Bithell, 1993a). Retraction of the fibrin stabilised clot may increase clot strength 
(Bithell, 1993a), draw wound edges together, and reduce the size of the thrombus to allow blood 
flow around it (Isenberg and Bainton, 1991) but the physiological significance of this is debated. The 
effect of clot retraction is greater in fibrin and platelet clots than in whole blood clots, where the 
presence of red blood cells impedes retraction (Bithell, 1993a). Attachment of platelets to the fibrin 
mesh occurs at the points where fibrin strands cross (Bithell, 1993a). The mechanism of this 
attachment is not understood (Bithell, 1993a). Contraction of platelet actin-myosin provides the 
force for clot retraction and requires thrombin and free calcium (Bithell, 1993a).
1.5.9. Constraints on platelet activation
There are several mechanisms which prevent uncontrolled amplification of aggregatory stimuli. The 
endothelial cell has an important role in actively degrading aggregatory agonists such as ATP, 
bradykinin, serotonin and prostaglandins (Bithell, 1993a). The endothelial surface protein 
thrombomodulin avidly binds excess thrombin rendering it incapable of activating platelets or 
cleaving fibrinogen (Ware and Heistad, 1993). This interaction leads to the formation of the 
anticoagulant protein C (Ware and Heistad, 1993). The endothelium also produces heparans which 
activate antithrombin III (which inactivates thrombin in plasma) (Bithell, 1993a). The presence of 
heparan anionic groups prevents platelet-endothelial adhesion by promoting the electronegativity of 
the endothelium, with resulting platelet repulsion (Moore, 1991).
When appropriately stimulated, endothelial cells release prostacyclin (PGI2) (Bithell, 1993a). 
Prostacyclin is a vasodilator, potent antagonist of platelet aggregation and also antagonises platelet 
adhesion (Bithell, 1993a). Its mechanism of action involves stimulation of adenyl cyclase, resulting 
in increased platelet cAMP concentrations and effects on transmembrane calcium transport
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(Moore, 1991). This may lead to inhibition of exposure of fibrinogen binding sites, inhibition of 
platelet spreading and blocking of the vWf receptor (Bithell, 1993a).
Endothelium-derived relaxing factor (EDRF, or endothelium-derived nitric oxide) is synthesised and 
released by endothelial cells (Ware and Heistad, 1993). Release of EDRF is stimulated by 
acetylcholine, histamine, bradykinin, substance P, ADP, ATP and thrombin (Moore, 1991). This 
nitric oxide stimulates guanyl cyclase in platelets and vascular smooth muscle. Consequent 
increasing cytosolic GMP results in relaxation of vascular smooth muscle and inhibition of platelet 
aggregation (Ware and Heistad, 1993), probably by influencing transmembrane calcium transport in 
a similar manner to cAMP (Moore, 1991). EDRF is inactivated by haemoglobin and hence its effects 
are likely to be concentrated near the vessel wall (Ware and Heistad, 1993).
Other factors that limit platelet aggregation include rapid inactivation of cyclooxygenase in activated 
platelets, modulating effects of plasma lipoproteins and 13-hydroxycatadecanoic acid, poorly 
defined proteins released from leukocytes and endothelium, rapid breakdown of free ADP by 
plasma adenyl cyclase and hydrogen peroxide production by leukocytes in exudates (Bithell, 
1993a). Release of plasminogen-activator inhibitor type-l from activated platelets neutralises the 
endothelial-derived tissue plasminogen activator (t-PA), which causes platelet aggregation (Ware 
and Heistad, 1993). High concentrations of ATP, adenosine and serotonin are themselves inhibitory 
(Bithell, 1993a). In addition, the fact that coagulant enzymes such as thrombin are attached to the 
surface of activated platelets aids in keeping them within the platelet plug and out of general 
circulation (Bithell, 1993a).
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2. A s sessm en t  of Platelet N um ber
2.1. M ethods  of Platelet Counting
2.1.1. Manual cell counting
2.1.1.1. Haemocytometer
Manual or visual cell counting can be performed using a haemocytometer. This glass counting 
chamber holds a defined volume of fluid within a marked counting area. Various types are available, 
the most commonly used are the Neubauer and improved Neubauer. In these the counting area is 
made up of 9 primary squares each 1 mm x 1 mm which are further subdivided, and the depth of 
fluid is 0.1 mm. Thus each primary square holds 0.1 pL (Figure 2.1). Phase contrast microscopy 
enables the platelets to be visualised as retractile bodies. A special thin bottomed (1 mm) counting 
chamber is best for optimal phase contrast effect (Dacie and Lewis, 1991a). Many veterinary 
laboratories use brightfield microscopy with field contrast increased by condenser adjustment 
(Weiser et al., 1989). However the presence of non-platelet particles of a similar size to platelets 
are difficult to distinguish using this technique, and their presence, such as in leukaemias with high 
leukocyte counts and leukocyte fragmentation, may mask a concurrent thrombocytopenia (Weiser 
eta!., 1989).
1 mm
Figure 2.1 Haemocytometer counting chamber.
Blood is normally diluted for counting in a haemocytometer to enable cells to be dispersed in a 
monolayer. Various diluents have been described. Formal-citrate diluent (1% formalin in 32 g/l
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trisodium citrate) which is also used for red cell counting, gives incorrectly low platelet counts, 
because intact red cells obscure platelets (Lewis et al., 1979). The platelet count decreases with 
increasing red cell count (Lewis et al., 1979). Additionally in cats the large size of platelets makes 
them more difficult to differentiate from red cells. Ammonium oxalate (1%) iyses red cells, however 
the resultant debris may be mistaken for platelets (Dacie and Lewis, 1984) and experience and care 
are needed. Variable degrees of platelet lysis have been associated with its use in bovine blood 
samples (Maxie, 1977). In cats, the use of this diluent may be associated with increased platelet 
aggregation (R.J. Barron, pers. com.). Aggregation of platelets may be associated with significant 
errors as the haemocytometer does not allow large platelet clumps to travel within its 0.1 mm depth 
and clumps are often seen collecting at the edges of the cover glass. Small platelet clumps may be 
seen within the counting area but the numbers of platelets within them may be impossible to count 
accurately.
Although considered by many to be the gold standard for platelet counting, the accuracy of 
haemocytometer counts is generally less than with automated counts in most species. The 
coefficient of variation for human platelet counting by the visual method is 8-10% and by automated 
methods is 3-4% (Dacie and Lewis, 1991a). Inherent errors in manual cell counting arise from the 
random distribution of cells in the counting chamber and are minimised by counting the cells in a 
larger area (Dacie and Lewis, 1991a). It is better to count the cells in a second haemocytometer 
with a second pipetting than to duplicate the count in a single chamber (Dacie and Lewis, 1991a). 
Technical errors include those arising from poor blood sampling, inadequate sample mixing, 
inaccurate pipetting, poor filling of haemocytometers and use of equipment of poor accuracy (Dacie 
and Lewis, 1991a). These can be minimised by careful technique, attention to cleanliness and use 
of equipment of known accuracy (Dacie and Lewis, 1991a). The use of phase contrast microscopy 
significantly reduces errors due to the counting of dirt particles as does the use of a commercial 
prepackaged diluent system (Unopette™, Becton, Dickinson and Company, Franklin Lakes, NJ 
USA) comprising 1% ammonium oxalate, which presumably contains less particulate matter than 
solutions prepared in the laboratory (Wertz and Koepke, 1977). However, this commercial system 
produces greater dilutional errors, resulting in an increased number of falsely low platelet counts 
(Wertz and Koepke, 1977).
2.1.1.2. Smear estimation
Platelet counts can be estimated from routinely stained smears by counting the number of platelets 
seen per 100 white cells and multiplying this by the white cell count (per pL) to give the platelet 
count per pL (Jain, 1986a). Another method involves determining the average number of platelets in 
5-10 oil immersion fields in the thin area of the smear (Tvedten, 1994a). A normal platelet count in 
the cat corresponds to 11-29 platelets per oil immersion field (Weiss, 1984). A third method is to 
consider each platelet seen per oil immersion field as equivalent to approximately 15 000 platelets
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per pL (Tvedten, 1994a). In dogs, smear estimations were found to correlate very highly with cell 
counts on the Technicon H-1 analyser (Tvedten et al., 1988). However if platelet clumping is 
present the technique is inaccurate (Tvedten, 1994a). Recently, Tasker et al., (1999) and Tasker 
and Mackin, (1999) showed that each feline platelet per oil immersion field corresponds to a 
circulating platelet count of 23.6 x 109/L if the field number (FN) of the microscope ocular is 18; 19.1 
x 109/L if the FN is 20; 15.8 x 109/L if the FN is 22; and 10.9 x 109/L if the FN is 26.5. The presence 
of platelet aggregates at the periphery of the smear is taken to indicate adequate platelet numbers 
for normal haemostasis (Tasker et al., 1999).
2.1.2. Automated cell counting
2.1.2.1. Aperture impedance counters
An aperture impedance method is used in Coulter counters (Beckman Coulter Inc, Fullerton CA, 
USA), the Sysmex (Sysmex Corporation, Kobe, Japan), the Celloscope (Boule Medical, Stockholm, 
Sweden), the Minos® Vet (Abx Hematologie, Montpellier, France) and the Cell-Dyn (Abbott 
Laboratories, Abbott Park, IL, USA) analysers. Blood is diluted in an isotonic electrolyte solution and 
drawn through an aperture. The magnitude of electrical resistance across the aperture is 
proportional to the size of the cells passing it and the frequency of changes in resistance indicates 
the numbers of cells (Tvedten, 1994b). In this type of analyser in which differentiation between 
platelet and red blood cells is by size alone, the overlap in sizes between normal feline platelets and 
red cells leads to errors in both counts, as well as to MPV estimates (Zelmanovic and Hetherington, 
1998). The magnitude of this error of the platelet count is much greater than for the red blood cells 
because of the 20-fold difference in relative numbers of each ceil type (Mischke et al., 1995). The 
presence of leukocyte fragments in leukaemias, which may be of a similar size to platelets, results 
in false high errors in platelet counts, and may mask a concurrent thrombocytopenia (Weiser et al., 
1989). Differential leukocyte counting can be achieved by the addition of a high frequency 
electromagnetic probe (England, 1996).
2.1.2.2. Laser (optical or light scatter) cell counters
Diluted cells pass a focused light source in single file and the resulting scattered light is converted 
into signals based on the size and internal complexity of cells (Dacie and Lewis, 1991a; Tvedten, 
1994b). These analysers include the Technicon H-1 analyser (Bayer Corporation, Tarrytown, NY, 
USA) and the Ortho ELT analyser (Ortho Diagnostic Systems, Westwood, Massachusetts, USA). 
Advances such as examining the light scatter from different angles, or measuring light absorption 
allows the analyser to detect subpopulations of white cells (a differential white cell count) (England, 
1996). A platelet histogram is produced allowing detection of platelet size variations (Tvedten,
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1994b). Platelet and red cell scattering patterns do not overlap, thereby avoiding the errors 
produced by impedance analysers (Zelmanovic and Hetherington, 1998). However, since platelet 
aggregates have a differing light scatter pattern to that of individual platelets, they are not included 
in the platelet count and hence aggregated blood samples result in inaccurate platelet counts 
(Zelmanovic and Hetherington, 1998). Analysis of platelet refractive index allows assessment of the 
state of platelet activation (Zelmanovic and Hetherington, 1998).
It is now possible to combine both aperture impedance and light scatter technologies in the same 
machine (England, 1996) (Table 2.1).
red cell and platelet 
counting channel
differential white cell channel
Cell-Dyn aperture impedance light scatter
Coulter STKS aperture impedance aperture impedance,
light scatter and electromagnetic probe
Sysmex aperture impedance aperture impedance and high frequency 
alternating current technology
Technicon H*3RTX light scatter light scatter and absorbance
Table 2.1 Technology used by some of the modem machines for cell counting
The accuracy of cell counts performed on these instruments is generally much greater than manual 
counts because of the much greater numbers of cells counted (Kjeldsberg, 1993). However platelet 
aggregation can produce a significant error in white cell counts and also in the red cell counts of 
very anaemic cats (Jain, 1986a). Error codes ("flags”) produced by automated cell analysers 
pinpoint those samples in which results may be unreliable or in which there may be abnormal cells 
present, necessitating smear evaluation for assessment (England, 1996). However in one study 
(Schrezenmeier et al., 1995) only 29-77% of falsely low human platelet counts triggered an error 
code in the Coulter T540 and Coulter STKS machines.
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2.1.2.3. Quantitative buffy coat analysers
This system involves separation of cells of various sizes in an expanded buffy coat layer by 
centrifugation in a specialised microhaematocrit tube (Thrall and Weiser, 1992). A cylindrical plastic 
float is used to expand the lengths of the buffy coat layers to allow their measurement. QBC (Idexx, 
New York, NY, USA) is an example of this type of analyser. Measurement of the width of various 
layers of cells gives a partial white cell differential count as well as a red cell count and platelet 
count. Indistinct band separation is a major technical problem (Tvedten, 1994b) as is variation of 
cell sizes in disease states and platelet clumping, which alter the relative density of the cells. In 
addition, large platelet aggregates are trapped above the float and are thus not included in the 
platelet-crit measurement (Levine et al., 1986). Examination of a blood film can help distinguish 
these problems. Good accuracy is obtained for red cell counts and white cell counts, but correlation 
with reference methods for platelet counts is only fair (Tvedten, 1994b).
2.1.2.4. Centrifugal-based laser analysers
The VS2000 (HemaTechnologies Ltd, Glasgow, UK) is a centrifugal-based laser analyser being 
developed at Glasgow University. It uses a laser to measure the density of the cloud of platelets at 
the top of the buffy coat of a spinning microhaematocrit tube. Cloud density is correlated with the 
platelet count (Adams, 1985). Serial measurements are taken along the length of the platelet layer 
and the resulting curve used to calculate a platelet count. This analyser also operates as a 
quantitative buffy coat analyser giving an accurate platelet-crit measurement. The laser is used to 
locate interfaces between air, plasma, platelets, white blood cells, red blood cells and the 
haematocrit seal and this allows accurate measurement of the lengths of the various layers without 
the use of a float to expand the buffy coat layers. Changes in the optical density of platelets occur 
with activation and aggregation (McNicol, 1996) and may be a source of error with this system. In 
addition, platelet aggregates may be trapped amongst the red cell layer leading to a falsely low 
platelet count (R.J. Barron, pers. Com.). However the use of this system appears to provide the 
best available automated method for measurement of platelet-crit in aggregated feline samples at 
this time (R.J. Barron, pers. com.).
2.1.2.5. Specific function of the Minos® Vet analyser
The measurement principle of the Minos® Vet (Abx Hematologie, Montpellier, France) is based on 
the variation of impedance caused by the passage of a particle through a calibrated micro-aperture. 
The blood sample is diluted with an iso-osmotic current-conductive electrolyte solution and then 
aspirated through the microaperture. As a cell passes through the aperture, the electrical resistance 
(impedance) between two electrodes placed either side of the aperture, increases in proportion to
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the cell's volume. A histogram is generated for analysis by plotting the number of impulses (cell 
count) versus pulse height (impedance or cell size). Threshold settings and pulse amplification are 
used to discriminate cells from noise and debris. Coincident passage of cells through the aperture 
is corrected by an algorithm incorporated into the analysis software (R.J. Barron, pers. com.).
The Minos is a twin-channel analyser. Red cells and platelets are analysed in one channel and 
white ceils in the other. The leukocyte dilution chamber uses a lOOp-diameter aperture. Addition of 
a red cell lysing reagent to the leukocyte diluting fluid excludes the red cells from the count. The 
leukocyte lower threshold is fixed around 30 fL. Simultaneously a portion of the leukocyte lysate is 
diverted into a haemoglobinometer for measurement of free haemoglobin by the 
cyanmethaemoglobin method at 540nm. The erythrocyte dilution chamber uses a 50p-diameter 
aperture. Platelet count is determined concurrently with the erythrocyte count. The platelet lower 
threshold is fixed at 2 fL. A fixed upper platelet and lower erythrocyte threshold of 17.5 fL is used 
for cats and 27 fL for dogs, which in most cases cuts the histogram at the trough between the 
platelets and red cells . These settings have been determined by the manufacturer. While there is 
no upper threshold for erythrocytes (other than the 50 p-diameter of the aperture) to discriminate 
small leukocytes from erythrocytes, the relative numbers of the two cells means that this is not 
usually a problem (R.J. Barron, pers. com.).
MCV is derived from analysis of the degree of impedance produced by each particle. The 
relationship between the degree of impedance (pulse height) and the particle size is determined in 
the factory by use of stabilised human blood. However impedance is influenced not only by the 
particle size, but also by the particle shape as it passes through the sensing zone. Red cells deform 
to become fusiform during flow through the aperture. Cell flexibility can vary with red cell membrane 
defects such as spherocytosis but also varies between species. Therefore a correction factor for 
each species must be determined on whole blood and is entered into the machine. It is calculated 
by comparing the analyser calculated packed cell volume (haematocrit, HCT) with the manually 
measured packed cell volume (PCV) of 30 samples. The PCV of these samples should be 
approximately 30% in order to minimise the error caused by trapped plasma. Platelet size 
calibration is not possible since a packed cell volume for platelets cannot be determined. This limits 
the accuracy of mean platelet volume (MPV) and "platelet-crit'' measurements, although they 
remain useful as comparative values (R.J. Barron, pers. com.).
2.1.2.6. Preparation of platelet rich plasma
A suspension of platelets in plasma, free from other cells, can be prepared by centrifugation or 
gravity sedimentation of a whole blood sample and aspiration of the uppermost platelet column. 
Counting of the obtained platelet rich plasma (PRP) solution can then be performed using any 
method described above. PRP is frequently used in experiments involving platelet counts and there
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is considerable agreement between automated and manual counts performed on PRP. However to 
avoid erythrocyte contamination only the upper part of the PRP is aspirated. Thus the platelet rich 
plasma obtained will not truly reflect the total platelet count, tending to be lower, than the whole 
blood platelet count, however the numerical effect of this may be minimised with some techniques 
(Zelmanovic and Hetherington, 1998) and it has been stated by others that sufficient accuracy 
should be obtained for clinical purposes (Weiser and Kociba, 1984). Considerable (though not 
statistically significant) falls in PRP platelet counts were found with time over 3 hours, with platelet 
aggregation or adherence to glass offered as explanations (Weiser and Kociba, 1984). Hence the 
problems produced by aggregation of platelets are not entirely overcome by methods using PRP. 
The use of PRP may also lead to reporting of a falsely low MPV, as large platelets have a greater 
buoyant density and concentrate at the lower levels of the PRP (Weiser and Kociba, 1984).
Addition of density gradient media to the sample facilitates separation of PRP from erythrocytes 
using sedimentation or centrifugation techniques (Greene et al., 1985). Successful application using 
centrifugation has been reported in a range of species, however, the technique was unsuccessful in 
feline samples because of the similarity in specific gravity of platelets and red blood cells (Greene et 
al., 1985).
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2.2. C hoice  of A nticoagulants
Inhibition of coagulation of the blood sample is required to allow examination of the cellular 
components of blood.
2.2.1. Ethylenediamine tetra-acetic acid (EDTA)
Salts of EDTA are powerful anticoagulants that work by chelating calcium which is required for 
clotting (Jain, 1986a). EDTA is generally preferred for examination of blood cell morphology (Jain, 
1986a), but is unsuitable for use for coagulation tests (Dacie and Lewis, 1991a). The use of dry 
salts avoids the dilution effects that occur with solutions. The disodium salt is less soluble than the 
dipotassium salt which is therefore the better of the two, and is commonly used at a concentration 
of 0.5-2.0 mg/mL of blood (Jain, 1986a). Commercially produced EDTA tubes ensure rapid solution 
of the EDTA by coating the container with a thin film of the salt.
Despite some contradictory evidence it is generally agreed that platelet swelling occurs in EDTA. 
This effect appears to be concentration and time dependent and can also be influenced by storage 
temperature and pH, and variations in these aspects of technique may explain contradictory 
findings (Waner et al., 1989). At concentrations of 0.15 mg/mL EDTA, canine platelets become 
spheroidal and develop long pseudopods, causing an increase in the measured MPV (Handagama 
et al., 1986). Similar changes in MPV have been noted in human samples (Handagama et al., 
1986) and are assumed to occur in feline samples (Zelmanovic and Hetherington, 1998). This 
change from discoid to spherical shape is potentially advantageous, allowing the application of Mie 
Scattering Theory (which applies to spherical bodies) for analysis of the light scattering data 
produced by laser cell counters such as the Bayer (Technicon) H*1 analyser (Zelmanovic and 
Hetherington, 1998). However changes in MPV with EDTA depend on the analyser used; in 
contrast to the Coulter counter, a decrease in MPV was noted with both the Minos and Bayer 
(Technicon) H*1 analysers because of the reduced optical density of swollen platelets (Byrne et al.,
1994).
Excessive EDTA can cause shrinkage of red and white blood cells, causing degenerative changes 
(Dacie and Lewis, 1991a) and can result in significant (5-10%) reductions in the PCV of feline blood 
at concentrations of 10 mg/mL and greater (Penny et al., 1970). This concentration would be 
achieved by the addition of only 1 mL of blood to a 5 mL EDTA vacutainer (Penny et al., 1970). 
Excess EDTA also causes platelet swelling and rupture in human blood samples, producing an 
artificially high platelet count, as thrombocyte fragments are large enough to be included in the 
platelet count (Dacie and Lewis, 1991a). Hence the importance of accurate filling of blood tubes 
and thorough mixing of the sample to obtain the correct final concentration.
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2.2.2. Heparin
Heparin is a natural tissue anticoagulant which forms complexes with antithrombin III to neutralise 
the action of thrombin and activated clotting factors XII, XI, IX and X (Jain, 1986a). These effects 
render it an unsuitable anticoagulant for use in coagulation studies (Jain, 1986a). Although it has 
the potential advantage of not altering red blood cell volume in excess concentrations, it is not used 
for examination of blood cell morphology because it interferes with the action of stains on the blood 
film (Jain, 1986a), and because of its tendency to induce white cell clumping (Dacie and Lewis, 
1991a; Kjeldsberg, 1993). Heparinised platelet rich plasma shows a greater tendency to 
spontaneous aggregation than citrated plasma (Newhouse and Clark, 1978).
2.2.3. Citrate
Salts of citrate prevent coagulation by chelating calcium (Jain, 1986a). Sodium citrate dihydrate is 
used as a 3.8% solution, in a 1 to 9 part dilution with blood for the study of platelet morphology and 
coagulation studies (Jain, 1986a; Narayanan, 1995). The optimal concentration of citrate to prevent 
platelet aggregation may be higher than this. Aggregatory responses of human platelets to collagen, 
adrenaline, ADP and serotonin which occurred when a final citrate concentration of 0.38% was 
used, were inhibited when the citrate concentration was increased to 0.64% (O'Brien et al., 1969). 
Because it introduces a dilutional effect citrate is not generally used for morphological studies of 
blood cells (Jain, 1986a). Platelets retain their discoid shape when collected into citrate 
(Handagama etal., 1986; Zelmanovic and Hetherington, 1998).
Citrate is used in combination with dextrose as acid-citrate-dextrose (ACD) and citrate-phosphate- 
dextrose (CPD) for long term preservation of whole blood and for transfusion purposes (Dacie and 
Lewis, 1991a).
2.2.4. Oxaiate
Salts of oxalate halt coagulation by precipitating calcium in insoluble crystals (Dacie and Lewis, 
1991a). Sodium and potassium oxalates are no longer in common use.
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2.2.5. Sodium fluoride
Sodium fluoride is used as to preserve concentrations of glucose for biochemical analysis, alone or 
in combination with other anticoagulants (Colville, 1992). Significant shrinkage of bovine red blood 
cells was found in sodium fluoride-potassium oxalate anticoagulant rendering samples unsuitable 
for haematological analysis (Manston etal., 1974).
2.2.6. Anticoagulant-induced pseudothrombocytopenia
For some time EDTA has been known to cause platelet aggregation in vitro in a small percentage 
of human individuals. The mechanism has been shown to involve the presence of antibody (in most 
cases IgG) and can be induced by mixing the serum of individuals in which it occurs with unaffected 
donor platelets in the presence of EDTA (Pegels et al., 1982). The antibody binds to the 
glycoprotein llb/llla complex and it is thought that this leads to platelet activation by mimicking 
binding of glycoprotein llb/lla ligands such as fibrinogen and fibronectin (Schrezenmeier et al., 
1995). Although early work demonstrating that EDTA-induced platelet aggregation was inhibited by 
addition of calcium, suggested that the mechanism involved calcium chelation by EDTA (Onder et 
al., 1980), this has been disputed by some authors who have demonstrated anticoagulant induced 
platelet aggregation in agents which do not cause chelation of calcium (Schrezenmeier et al.,
1995).
Anticoagulant-induced pseudothrombocytopenia has now been demonstrated using a variety of 
anticoagulants such as EDTA, heparin, oxalate and citrate (Schrezenmeier et al., 1995). EDTA 
causes the greatest aggregatory effect in a time dependent and concentration dependent manner, 
with ACD (acid-citrate-dextrose) having the least effect (Schrezenmeier etal., 1995). Aggregation of 
the platelets prevents them from being counted by either automated counters or haemocytometer, 
resulting in a falsely low platelet count, however aggregates are clearly visible on smears in all 
cases (Schrezenmeier et al., 1995). Concurrent falsely elevated white cell counts 
(pseudoleukocytosis) may occur using automated counting because the large platelet aggregates 
mimic leukocytes in size (Schrezenmeier et al., 1995). At present concurrent 
pseudothrombocytopenia and pseudoleukocytosis has only been demonstrated with the 
anticoagulant EDTA and may depend on the type of cell counter used (Schrezenmeier et al., 1995). 
EDTA-induced pseudothrombocytopenia has been documented in the horse (Hinchcliff et al., 1993; 
Boudreaux, 1996)) and pig (Ragan, 1972), and is thought to occur in the dog and cat (Hodson and 
Mackin, 1998). Whether this contributes to the propensity for feline blood samples to aggregate in 
vitro is not clear.
Platelet rosetting around neutrophils (termed platelet satellism) is another in vitro phenomenon 
seen in some human blood samples with EDTA as an anticoagulant held at room temperature. In
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this case it is thought that EDTA-dependent antibodies link the platelet glycoprotein llb/llla complex 
and the neutrophil Fc(gamma) receptor. This process may also result in spurious thrombocytopenia 
(Shahab and Evans, 1998).
2.3. Effects  of  Storage  on B lood
Storage of human blood at room temperature causes progressive red cell swelling, increased 
osmotic fragility and prothrombin time and falls in leukocyte and platelet counts which can be 
striking by 12-18 hours (Dacie and Lewis, 1991a). These changes are more marked with EDTA but 
also occur with other anticoagulants (Dacie and Lewis, 1991a). At 4°C some of these changes are 
arrested (Dacie and Lewis, 1991a). In cats storage of blood for 48 hours at 4°C had little effect on 
the PCV when EDTA concentrations were less than 5 mg/mL (Penny et al., 1970). There was a 
species difference in the effect on PCV of storage at room temperature, with significant red cell 
swelling noted in dogs after 24 hours and little effect noted in either feline or equine samples after 
72 hours (Penny et al., 1970). Storage of canine blood samples at 4°C resulted in progressive 
development of pseudopods in platelets over 4 hours, an effect that was amplified when EDTA (at 
0.15 mg/mL) was used as the anticoagulant (Handagama et al., 1986). Less change was noted 
during storage at 37 degrees (Handagama et al., 1986). MPV increases with storage time (Weiser 
and Kociba, 1984). Laboratory experience is that with storage of samples there is a progressive 
decrease in platelet count and an increase in haemolysis. While not statistically significant, the 
progressive decrease reported in feline platelet counts over 3 hours at room temperature (Weiser 
and Kociba, 1984), supports this observation. It is therefore advisable to make a blood film for 
evaluation as soon as possible after collection (Dacie and Lewis, 1991a).
The ability of platelets to aggregate is affected by plasma pH (Newhouse and Clark, 1978). The 
aggregatory response to agonists of human platelets is generally inhibited below a pH of 6.4 and 
above a pH of 10, with the optimum pH being approximately 8 (Newhouse and Clark, 1978). 
However this is influenced by the concentration and acid-base properties of the aggregating agent 
employed (Newhouse and Clark, 1978). pH rises with time in blood samples as carbon dioxide 
diffuses out of solution. Factors influencing this diffusion include the surface area to volume ratio of 
the sample, whether the sample is capped and mixing of the sample (Newhouse and Clark, 1978). 
Changes in aggregatory response induced by pH may be due to changes in calcium concentrations, 
the platelet membrane, the rapidity of ADP catabolism, net surface charge of platelets or changes 
in cAMP metabolism (Newhouse and Clark, 1978).
As storage temperature of platelets decreases the tendency for spontaneous aggregation increases 
(Newhouse and Clark, 1978).
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3. Feline  P latelet D isorders
The normal platelet count for the cat appears to be somewhere In the range of 300 to 800 x 109/L 
(Jain, 1993). In a study on platelet counts of healthy cats under ketamine anaesthesia (Weiser and 
Kociba, 1984) found the mean platelet count to be 460 x 109/L (range 263-840 x 109/L). Age, breed 
and sex have little effect on platelet count, with only the very young (less than 3 months old) having 
lower platelet counts than adults (Jain, 1993). Increases in platelet count and PCV are seen 
following “fright” (Jain, 1986a; Hammer and Couto, 1994) and is thought to be due to adrenalin 
related contraction of the splenic pool. While the effect of general anaesthesia on platelet count in 
cats does not appear to have been evaluated, PCV has been shown to decline, presumably due to 
relaxation of the spleen and splenic pooling (Frankel and Hawkey, 1980). Thus it is likely that the 
platelet counts in anaesthetised cats will be consistently less than unanaesthetised cats. The 
unpredictable degree of adrenalin release when sampling conscious cats is likely to result in a wide 
range of “normal” platelet counts.
Time of analysis after sampling may affect the platelet count due to in vitro platelet clumping. In one 
study substantial reductions in platelet counts in both whole blood and PRP were found over a 3 
hour period after sampling (both changing by approximately 100 x 109/L as estimated from the 
graphs), but these were not statistically significant (Weiser and Kociba, 1984).
Spontaneous bleeding is an uncommon clinical sign in the cat, however abnormal coagulation 
profiles are found relatively frequently in sick cats (Couto and Hammer, 1994). The most common 
abnormalities in laboratory findings are those consistent with disseminated intravascular 
coagulation (DIC) and intrinsic coagulation cascade abnormalities (Couto and Hammer, 1994).
page 46
feline thrombocytopenia
3.1. Feline  T hro m bo cytopenia
Thrombocytopenia appears to be a rare cause of clinical disease in the cat (Couto and Hammer,
1994). In a survey of 3300 feline blood samples, thrombocytopenia (platelet count less than 200 x 
109/L) was observed in 41 (1.2%) cases (Jordan et al., 1993). This compares to an incidence of 
5.2% in dogs (Grindem etal., 1991). Only 14 of 41 cats with thrombocytopenia had clinical signs of 
abnormal haemostasis (Jordan etal., 1993).
When present, the most common cause of feline thrombocytopenia is bone marrow failure, with 
neoplasia and/or retroviral infections commonly implicated (Couto and Hammer, 1994). Sixteen of 
41 cats (39%) with thrombocytopenia had at least one neoplasm, and 13 of these were either 
leukaemia or lymphosarcoma (Jordan et al, 1993). Malignancy is a common cause of 
thrombocytopenia in the dog, however the pathogenesis is thought to be multifactorial, involving 
decreased thrombopoiesis, immune mediated destruction and DIC-related consumption of platelets 
(Helfand, 1988). Acute leukaemias result in thrombocytopenia in more than 90% of human patients 
and results from megakaryocyte hypoplasia (Athens and Ward, 1993). Moderate thrombocytopenia 
can also be seen in human chronic leukaemias and multiple myeloma but is unusual in lymphoma 
and polycythemia vera prior to cytotoxic therapy (Athens and Ward, 1993). Thrombocytopenia is 
common in dogs with haemopoietic neoplasia (58% of 41 cases) but also occurred in 20% of 59 
cases with solid non-haemolymphatic neoplasia (Madewell et al., 1980). Myelophthisic diseases 
uncommonly result in thrombocytopenia in human patients (in some cases even resulting in 
thrombocytosis) and the mechanism by which invasion of the marrow by neoplastic cells can impair 
thrombopoiesis remains unclear (Bithell, 1993d). Proposed mechanisms include competition 
between tumour ceils and myeloid cells for nutrients, occlusion of marrow blood supply by tumour 
emboli, lysis of marrow cells by adjacent tumour cells and production of inhibitory factors by tumour 
cells (Helfand, 1988). In a review of 14 dogs with myelofibrosis, platelet and megakaryocyte counts 
were generally normal to increased despite the presence of a moderate to marked poorly 
responsive anaemia in most dogs (Hoff et al, 1991). Increasingly, autoimmune destruction of 
platelets in human patients with haemopoietic and other neoplasms is being recognised as a 
contributor to thrombocytopenia (Athens and Ward, 1993). Ineffective thrombopoiesis (in which 
platelet production is reduced despite normal to increased megakaryocyte numbers) and platelet 
pooling in an enlarged spleen contribute to thrombocytopenia in some cases (Athens and Ward,
1993).
Of 37 thrombocytopenic cats tested 11 (30%) were infected with feline leukaemia virus (FeLV), 3 of 
these with concurrent haemic neoplasia, and 2 of 13 cats tested (15%) were infected with feline 
immunodeficiency virus (FIV) (Jordan et al, 1993). Human thrombocytopenia can be associated 
with various infectious agents such as rubella, live measles vaccination, influenza, septicaemia, 
malaria and trypanosomiasis (Bithell, 1993d). Mechanisms of viral infection induced 
thrombocytopenia involve viral invasion of megakaryocytes and platelets, and viral-antibody 
immune complex development (Bithell, 1993d). The development of mild thrombocytopenia in cats
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infected with FeLV is thought to primarily result from the infection of megakaryocytes (Rojko and 
Hardy, Jr., 1994). Infection of both megakaryocytes and platelets has been demonstrated in FeLV 
viraemic cats (Boyce et al., 1986). Platelets may become very large due to expansion of 
megakaryocyte cytoplasm without concomitant increase in the area of demarcation membrane 
(Boyce et al., 1986). Defects in platelet function have also been noted, but clinical signs of bleeding 
are uncommon (Kociba, 1986). Immune mediated platelet destruction may contribute to 
thrombocytopenia. Circulating immune complexes have been demonstrated in some FeLV infected 
cats and may react with FeLV antigens expressed by platelets (Boyce et al., 1986). The 
mechanisms of development of thrombocytopenia and other blood cell abnormalities in FIV infected 
cats remains unclear and are likely to be multifactorial. Although FIV-related RNA can be found in 
some megakaryocytes and other bone marrow cells (Pedersen and Barlough, 1991), there does not 
appear to be a direct effect of the virus on blood cell precursors (Shelton et al., 1991). A serum 
inhibitory factor (possibly antibody) has been demonstrated (Shelton et al., 1991) and immune 
mediated thrombocytopenia has been reported (Pedersen and Barlough, 1991). Eight to 10% of 
FIV-positive cats have thrombocytopenia (Shelton etal., 1991; Hart and Nolte, 1994).
Severe thrombocytopenia in FIP can result from vasculitis and development of DIC (Weiss et al., 
1980), and it is thought that an early, direct effect of the virus on platelets may contribute to the 
tendency to enhanced aggregation and thrombocytopenia (Boudreaux et al., 1990a; Boudreaux et 
al., 1990b). Human thrombocytopenia may be seen in septicaemia in the absence of DIC and may 
be due to platelet-bacterial interactions, endotoxaemia, platelet interactions with immune complexes 
and with damaged vascular surfaces (Bithell, 1993d). Parasitism of platelets, immune processes, 
intravascular coagulation and hypersplenism may all play a role in parasite-induced 
thrombocytopenia (Bithell, 1993d). Other infections that have been associated with 
thrombocytopenia in cats include feline panleukopenia, toxoplasmosis and haemobartonellosis 
(Jordan et al., 1993), cytauxzoonosis (Hoover et al., 1994), ehrlichiosis (Breitschwerdt, 1995) and 
histoplasmosis (Wolf and Troy, 1995).
Cardiac diseases were found in 4 (9%) of 41 cats with thrombocytopenia and in 3 of these cases 
there were clinical signs of haemostatic abnormalities (Jordan et al., 1993). The cause of 
thrombocytopenia may be related to development of DIC (Bonagura, 1994). The platelets of cats 
with cardiomyopathy show increased in vitro aggregation (Welles et al., 1994a).
DIC represents one of the most common causes of abnormalities of haemostatic profiles in the cat, 
however it is rarely symptomatic (Couto and Hammer, 1994). DIC was diagnosed in 5 (12%) of 41 
cats with thrombocytopenia in one study (Jordan et al., 1993) and in another, 21 (21%) of 106 cats 
undergoing coagulation testing fulfilled all the criteria for diagnosis of DIC (Couto and Hammer,
1994). Neoplasia, hepatic disease or feline infectious peritonitis are present in the majority of cats 
with DIC (Couto and Hammer, 1994).
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Primary immune mediated thrombocytopenia was diagnosed in only 1 of 41 cats with 
thrombocytopenia (Jordan et al., 1993) and, in contrast to the dog, represents a rare cause of 
thrombocytopenia in the cat (Couto and Hammer, 1994). Drug induced thrombocytopenias also 
appear to be uncommon (Couto and Hammer, 1994).
Haemorrhage does not cause significant reductions in platelet count. In haemorrhage platelets are 
lost along with other blood cells, however significant thrombocytopenias are not produced because 
the amount of blood that would need to be lost, would result in the death of the animal (Hodson and 
Mackin, 1998). The exception is if stored blood is used to replace massive blood loss, in which case 
dilutional thrombocytopenia occurs (Bithell, 1993d). This can be avoided in humans patients by 
administration of 1 unit of fresh whole blood for every 5 units of stored whole blood (Bithell, 1993d).
page 49
feline thrombopathia
3.2. D iso rd e rs  o f  P la te le t  Function
Disorders of platelet function are being increasingly recognised in man and may complicate a wide 
variety of hereditary and acquired diseases (Bithell, 1993e) (Table 3.1). Often however, these have 
little clinical significance in the absence of concurrent coagulation abnormalities (Bithell, 1993e). 
The suspicion of a disturbance of platelet function may arise when bleeding time is prolonged, but 
platelet counts are normal or only mild to moderately decreased (de Gopegui and Feldman, 1998). 
Abnormalities of platelet size and shape may also suggest a platelet defect. Confirmation requires 
specific in vitro tests of platelet function and immunoassays (Table 3.2) some of which are not 
commonly available in commercial veterinary laboratories.
Test Function evaluated
buccal mucosal bleeding time * in vivo platelet function
glass bead retention test * platelet adherence
clot retraction in response to thrombin * qualitative and quantitative integrin at|bp3
fibrin and FDP assay * inhibitors of platelet aggregation
vWf:Ag assay 9 platelet adherence
aggregation in response to agonists platelet aggregation
nucleotide contents platelet ADP/ATP contents
cAMP intracellular cAMP content
thromboxane assay platelet thromboxane B2 production
protein phosphorylation protein kinase C activation
serotonin assay platelet dense granule secretion
p-thromboglobulin assay platelet alpha granule secretion, 
in vivo platelet activation
8-glucuronidase assay platelet lysosomal granule secretion
electron microscopy platelet morphology
glycoprotein electrophoresis deficiencies of glycoproteins/integrins
Table 3.2 Platelet function tests (Clemetson, 1996; McNicol, 1996; de Gopegui and Feldman, 
1998)
* Requires a normal number of platelets (Davenport et al, 1982; Day and Rao, 1986).
* Because fibrinogen and vWf are essential for normal platelet function, their quantification should 
precede other platelet function tests (de Gopegui and Feldman, 1998).
Disturbances of platelet function can be the result of abnormalities in any part of the complex 
physiology of the platelet and particular diseases have increased the understanding of platelet 
physiology. In other uncommon and poorly documented platelet function disorders the 
pathophysiology is still being elucidated. Acquired platelet disorders make up the majority of cases 
of functional disturbance, with drug therapy being the most common of these (de Gopegui and 
Feldman, 1998). They are also found secondary to many diseases including renal disease, liver 
disease, dysproteinaemias, infectious processes, immune mediated disease, and DIC (Table 3.1).
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3.2.1. Acquired platelet function disorders
3.2.1.1. Drugs
A wide variety of drugs have been associated with impaired platelet function in man (Table 3.1) and 
many of these agents are known (or are likely) to have effects on feline platelets. Aspirin inhibits 
platelet release reaction by irreversibly inactivating platelet cyclooxygenase and blocking 
thromboxane and prostaglandin synthesis for the life of the platelet (Bithell, 1993e). Other non 
steroidal anti-inflammatory drugs have differing degrees of reversible or irreversible effect on 
platelet cyclooxygenase (Bithell, 1993e). inhibition of platelet phosphodiesterase by dipyridamole, 
papaverine and methyxanthines inhibits aggregation and release reaction (Bithell, 1993e). Nitric 
oxide donors stimulate adenyl cyclase and guanyl cyclase with the same effect on the platelet (de 
Gopegui and Feldman, 1998). Calcium channel blockers interfere with signal transduction within the 
platelet, inhibiting adhesion, aggregation and release reaction but do not prolong bleeding time 
(Bithell, 1993e). Other drugs may contribute to platelet dysfunction by stabilising mitochondrial and 
cell membranes, destabilising phospholipid bilayer structure, coating of platelet membranes and 
altering surface charge, or by unknown mechanisms (Bithell, 1993e).
3.2.1.2. Uraemia
Platelet dysfunction is a clinically important feature of the bleeding diathesis which accompanies 
human uraemia (Bithell, 1993e). Platelet function abnormalities include deficiencies of release 
reaction and aggregation (Bithell, 1993e) and it is likely that these changes are the result of the 
accumulation of several uraemic metabolites (Bithell, 1993e). Low molecular weight peptides with a 
common amino acid sequence to adhesive proteins bind membrane integrins and impair 
aggregation (de Gopegui and Feldman, 1998). Acquired storage pool deficiencies may also 
contribute to platelet dysfunction in uraemia (Bithell, 1993e). Abnormalities in platelet and 
endothelial prostaglandin production are also present and are thought to be due to another non- 
dialyzable factor (Bithell, 1993e). There is an increase in endothelial prostacyclin production with 
concurrent decreased platelet prostaglandin production leading to impaired aggregation (Bithell, 
1993e). Treatment with cryoprecipitate or DDAVP can temporarily control bleeding in uraemic 
patients but the reason for this effect is unclear (Bithell, 1993e). Although there is some evidence of 
abnormalities of platelet vWf receptors, plasma vWf concentrations and multimer distribution 
appear to be normal in uraemia (Bithell, 1993e). Response to oestrogens is also not understood 
(Bithell, 1993e). Prolonged buccal mucosal bleeding times have been reported in uraemic dogs 
(Jergens et al., 1987), but no abnormalities in platelet aggregation were found using a whole blood 
impedance method in uraemic dogs (Forsthye et al., 1989). Hart and Nolte, (1991) found no 
abnormalities in platelet aggregation in two cats with uraemia.
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3.2.1.3. Fibrin degradation products
Accumulation of fibrin degradation products (FDP) can impair platelet aggregation in vitro, and 
concentrations of FDP have been correlated with platelet dysfunction in dogs and severity of 
bleeding in some human patients with DIC and cirrhosis (Bithell, 1993e). However elevated FDP 
concentrations do not entirely explain the platelet function defects seen in these disorders (Bithell, 
1993e). In DIC, storage pool deficiency and direct effects of plasmin may also be involved (Bithell, 
1993e). In cirrhosis, acquired deficiency of glycoprotein I (Bithell, 1993e), and increased nitric oxide 
production from ammonia metabolism (de Gopegui and Feldman, 1998), may also have a role. 
Reduced platelet aggregation in response to collagen and arachidonic acid has been demonstrated 
in dogs with naturally occurring liver disease (Willis et al., 1989).
3.2.1.4. Paraproteinaemias and haemopoietic diseases
Platelet dysfunction may occur as part of the spectrum of abnormalities of haemostasis seen with 
paraproteinaemias in humans (Bithell, 1993e). It is most commonly seen in association with 
macroglobulinaemia (Bithell, 1993e). The coating of platelets with abnormal proteins is thought to 
displace normal proteins and interfere with agonist binding (Bithell, 1993e). In human acute 
myeloblastic leukaemias and preleukaemias, morphological platelet defects are present because of 
abnormal thrombopoiesis, resulting in deficient nucleotide storage and release reaction, and 
accompany thrombocytopenia and DIC to complicate the haemorrhagic diathesis (Bithell, 1993e). 
Chronic myeloproliferative disorders of several types cause platelet dysfunction in humans (see 
Table 3.1) (Bithell, 1993e). Mechanisms of platelet dysfunction include acquired storage pool 
disease, PF-3 deficiency and deficient membrane glycoproteins (Bithell, 1993e).
3.2.1.5. Immune mediated thrombocytopenia
Platelet dysfunction accompanying immune mediated thrombocytopenia has been demonstrated in 
humans and dogs but its clinical significance has not been determined (Bithell, 1993f; Kristensen et 
al., 1994). There is evidence to suggest that antibody in immune mediated thrombocytopenia may 
bind the glycoprotein llb/llla complex (Woods et al., 1984; Bithell, 1993f; Curtis et al., 1994) and, 
less frequently, other membrane glycoproteins (Chong et al., 1991; Clemetson, 1996) manifesting 
as platelet dysfunction when there is insufficient quantity to result in clearance by the monocyte 
macrophage phagocytic system (Bithell, 1993f); (Bithell, 1993e). Reversible platelet activation by 
antibodies may also result in acquired storage pool deficiency (Bithell, 1993f).
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3.2.1.6. Diet
Arachidonic acid is an essential fatty acid in the cat and its deficiency results in a mild impairment of 
aggregation in response to ADP, collagen and arachidonic acid (Callan and Giger, 1997). 
Supplementation with n-3 fatty acids may moderately inhibit platelet function by decreasing the 
amount of available arachidonic acid for thromboxane A2 synthesis (Bithell, 1993e; Hall, 1996), 
however no change of platelet function could be demonstrated in one study in cats (Bright et al., 
1994).
3.2.1.7. Infections
Feline leukaemia virus infection causes a measurable inhibition of platelet aggregation in response 
to certain agonists but no clinical significant bleeding tendency has been associated with this 
(Kociba, 1986). No abnormalities in platelet function were demonstrated in one study of FIV infected 
cats (Hart and Nolte, 1994). Infectious canine diseases such as ehrlichiosis (Harrus et al., 1996) 
and parvoviral enteritis (de Gopegui and Feldman, 1998) are associated with platelet function 
defects in addition to thrombocytopenia.
Enhanced platelet aggregatory responses to in vitro agonists has been demonstrated in cats 
infected with feline infectious peritonitis (FIP) virus, which may be a result of a direct viral effect on 
platelets (Boudreaux etal., 1990a; Boudreaux etal., 1990b). Platelet hyperreactivity has also been 
demonstrated in the early stages of canine rickettsial infection (Grindem et al., 1990).
3.2.2. Hereditary platelet function disorders
Few hereditary thrombocytopathies have been recognised in the cat. Two hereditary feline diseases 
which cause abnormalities in platelet function are Ch&diak-Higashi syndrome and von Willebrand’s 
disease.
3.2.2.1. Chediak-Higashi syndrome (CHS)
Ch&diak-Higashi syndrome is an autosomal recessive disorder of Persian cats which occurs in 
several other species including man (Prieur and Collier, 1981; Baldwin and Cowell, 1997). This 
multisystem disorder results from abnormal granule fusion, with larger and fewer than normal (and 
perhaps defective) granules formed in most granule-containing cells through the body (Athens, 
1993). The abnormal granules may arise from dilated portions of the Golgi-endoplasmic reticulum-
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lysosome apparatus, but exactly how they are formed remains unclear (Athens, 1993). Affected 
organs include haematopoietic tissues, hair, ocular pigment, skin, adrenal glands, pituitary, 
gastrointestinal tract, peripheral lymph nodes, kidney, vascular endothelium and fibroblasts (Athens, 
1993). A consistent feature in various tissues is that the granule contents are that of the normal cell 
(Athens, 1993).
In cats, CHS is recognised by the obvious pigmentation abnormality including pale blue-smoke 
(diluted) coat colour, yellow-green irises and altered fundic pigmentation (Prieur et al., 1979; 
Baldwin and Cowell, 1997). The finding of abnormal granules in neutrophils, eosinophils and hair 
shafts of affected cats can be used to confirm the diagnosis (Kramer et al., 1977; Prieur et al., 
1979).
Ch6diak-Higashi syndrome results in a virtual absence of platelet dense granules and their 
contents; adenine nucleotides, serotonin and calcium (Meyers et al., 1982). It may be classified as 
a “storage pool disease” in which there are deficiencies of platelet granule contents leading to 
deficient platelet responses (Baldwin and Cowell, 1997). Deficiencies in platelet aggregatory 
response to agonists have been demonstrated (Meyers et al., 1982), and affected cats have 
bleeding tendencies (Prieur et al., 1979) and prolonged buccal mucosal bleeding times (Parker et 
al., 1988) but platelet numbers are normal (Prieur et al., 1979; Baldwin and Cowell, 1997). Death 
from acute haemorrhage may occur (Guilford, 1987).
Increased susceptibility to infection because of abnormal neutrophil function is a feature of the 
disease in humans and mink (Athens, 1993), and neutrophil dysfunction (Guilford, 1987; Colgan et 
al., 1992) and neutropenia (Prieur and Collier, 1987) have been documented in affected cats. 
Affected cats have a shortened lifespan with an increased incidence of neonatal septicaemia, viral 
and chlamydial respiratory infections (Guilford, 1987). In the late stages of human Chediak-Higashi 
syndrome lymphadenopathy, hepatosplenomegaly, neuropathy, anaemia, neutropenia and less 
often, thrombocytopenia occur, with widespread tissue infiltration with mononuclear cells (Athens,
1993), however this phase has not been reported in animals (Kramer et al., 1977).
3.2.2.2. von Willebrand’s disease (vWD)
Deficiency of von Willebrand’s factor results in platelet dysfunction and illustrates the importance of 
this factor in platelet adhesion, von Willebrand’s disease is an autosomal group of disorders which 
may be the most common inherited bleeding disorder of dogs and humans (Dodds, 1991; Bithell, 
1993g; de Gopegui and Feldman, 1998). However the disease has only been reported in one cat 
(French et al., 1987). The disease is characterised by subnormal concentrations of vWf, with a 
resultant deficiency of platelet adhesion to collagen, prolongation of bleeding time and clinical signs 
relating to defects in primary haemostasis: petechiation, mucosal bleeding and prolonged bleeding
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following surgery. A validated assay for feline vWf:Ag concentration is now available (Callan and 
Giger, 1997) and some authors suspect this may lead to the diagnosis being more commonly made 
in cats (Dodds, 1991; Callan and Giger, 1997).
3.2.2.3. Other hereditary platelet function disorders
Recently two cats have been reported with a bleeding disorder characterised by defects in platelet 
aggregation and storage of adenine nucleotides, resembling a storage pool deficiency (Callan and 
Giger, 1997; de Gopegui and Feldman, 1998).
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Table 3.1 Disorders of platelet function in man (Bithell, 1993e).
A: Hereditary disorders
Pure platelet dysfunctions
Platelet dysfunctions associated with mild- 
moderate thrombocytopenia
Platelet dysfunction associated with multisystem 
disease
1. Glanzmann’s thrombasthenia
2. Deficient release reactions (including storage
pool disease, Hermansky-Pudiak syndrome, 
cyclooxygenase deficiency, others)
1. Bernard Soulier syndrome
2. Wiskott-Aldrich syndrome
3. Thrombopathic’ thrombocytopenia
4. ‘Montreal’ platelet syndrome
5. Gray platelet syndrome
1. Hereditary afibrinogenaemia
2. Heritable connective tissue disorders
(including Marfan syndrome, osteogenesis 
imperfecta, Ehrlers-Danlos syndrome, 
mucopolysaccharidoses)
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Table 3.1 continued Disorders of platelet function in man (Bithell, 1993e). 
B: Acquired disorders
Drugs: (those shown to impair platelet function at 
therapeutic concentrations)
2.
3.
antiinflammatories including aspirin, 
phenylbutazone, indomethacin 
antimicrobials including ampiciliin, penicillin, 
carbenicillin, nitrofurantoin 
antidepressants including amitryptiline, 
chlorpromazine, cyproheptadine, 
phenothiazines, reserpine 
adrenergic blockers including propanolol, 
phentolamine 
miscellaneous drugs including antihistamines, 
amrinone, daunorubicin, dextrans, 
dipyridamole, ethanol, furosemide, glicazide, 
heparin, local and general anaesthetics, 
methylxanthines, radiographic contrast 
agents, sulfonylureas, ticlopidine, verapamil 
and other calcium channel blockers, 
vitamin E
Diseases of the haematopoietic system 1. paraproteinaemias (including
macroglobulinaemia, multiple myeloma)
2. acute myeloblastic leukaemias and
preleukaemias
3. chronic myeloproliferative disorders (including
myelofibrosis, polycythemia vera, chronic 
myelocytic leukaemia, thrombocythaemia)
4. miscellaneous haematopoietic diseases
(including idiopathic thrombocytopenic 
purpura, p-thalassaemia, sickle cell 
anaemia, leukaemic reticuloendotheliosis, 
SLE, haemophilia A, G6PD * deficiency, 
infectious mononucleosis)
Disorders associated with increased fibrin 
degradation products (FDP)
1. DIC
2. fibrinogenolysis
3. liver disease
Uraemia
Miscellaneous congenital heart disease, following extracorporeal 
circulation, hypothermia, microangiopathic 
haemolytic anaemias, congenital 
agammaglobulinaemia, essential fatty acid 
deficiency, post renal transplantation, scurvy, 
some glycogen storage diseases
* glucose-6- phosphate dehydrogenase
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3.3. Feline  T hro m bo cytosis  a n d  T h ro m bo cythaem ia
3.3.1. Physiological thrombocytosis
Physiological thrombocytosis occurs transiently after heavy exercise, parturition and adrenalin 
administration in humans because of mobilisation of the splenic and non splenic pools (Bithell, 
1993h). Adrenalin administration or excitement in cats results in physiologic thrombocytosis (Jain, 
1986a; Jain, 1993; Hammer and Couto, 1994).
3.3.2. Reactive thrombocytosis
In reactive or secondary thrombocytosis the platelet count increases because of an increase in 
megakaryocyte mass and is inversely correlated with the mean megakaryocyte volume (Bithell, 
1993h). There is a failure of rising platelet numbers to reduce the stimulus for nuclear 
endoreduplication in megakaryocyte precursors, but in most cases the factors leading to this 
process remain obscure (Bithell, 1993h).
Human reactive thrombocytosis occurs in conditions of accelerated erythropoiesis such as following 
acute haemorrhage, haemolytic anaemias and renal neoplasia, suggesting a link between 
erythropoietic and thrombopoietic control mechanisms (Bithell, 1993h). Mild thrombocytosis is 
commonly associated with iron deficiency anaemia in humans (Bithell, 1993h). It has been 
observed in dogs with iron deficiency (Harvey et al., 1982; Jain, 1986a), and in a cat with iron 
deficiency anaemia (Fulton et al., 1988). An “overshoot” thrombocytosis may be seen following 
recovery from thrombocytopenias of various types (Helfand, 1988; Bithell, 1993h). Reactive 
thrombocytosis is associated with several types of human neoplasia such as Hodgkin’s disease, 
breast carcinoma and lung carcinoma (Bithell, 1993h). Three of 59 dogs (5%) with non- 
haemolymphatic neoplasia were found to have thrombocytosis (2 had osteosarcoma and one had 
gingival carcinoma) (Madewell et al., 1980). Reactive thrombocytosis is also seen in a variety of 
human inflammatory disorders such as rheumatoid arthritis, tuberculosis, osteomyelitis, ulcerative 
colitis and in cirrhosis (Bithell, 1993h). Platelet count has been found to rise and fall during the 
course of bacterial infection and recovery in various species (Hawkey et al., 1990). Thrombocytosis 
may be seen in humans following major surgical procedures other than splenectomy (Davis and 
Mendez Ross, 1973; Jain, 1986a; Bithell, 1993h). It is common during human pregnancy and the 
puerperium (Bithell, 1993h) and during the growth phase of many species (Hawkey et al., 1990).
Reactive thrombocytosis is common following splenectomy in humans (Bithell, 1993h). The 
mechanism is unknown, but the degree of thrombocytosis may be massive, more than can be 
accounted for by circulation of platelets normally held in the splenic pool (Bithell, 1993h). Platelet 
counts begin to rise 1 to 10 days following splenectomy to peak in 1-3 weeks (Davis and Mendez 
Ross, 1973; Bithell, 1993h). No abnormality of platelet function has been demonstrated although
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platelet serotonin concentrations are decreased (Bithell, 1993h). In most cases platelet count 
gradually returns to normal but this process may take years in some cases (Davis and Mendez 
Ross, 1973; Bithell, 1993h). Post splenectomy thrombocytosis is rarely associated with the 
thromboembolic or haemorrhagic complications which can complicate primary (essential) 
thrombocythaemia in man (Bithell, 1993h). Reactive thrombocytosis has been reported in the dog 
following splenectomy (Jain, 1986a), however no consistent changes in canine platelet count were 
seen 10 days following splenectomy in another study (Richardson and Brown, 1996). Decreased 
feline platelet counts following splenectomy have been reported (Jain, 1986a), as have increased 
platelet counts (Lawrence and Valentine, 1947). The incidence of each in cats following 
splenectomy has not been reported. This may be because disease of the feline spleen appears to 
be less common than that of the canine spleen. Canine splenic samples were submitted for 
histopathological examination approximately 4 times more frequently than feline splenic samples 
over a similar 4 year period to one laboratory (Spangler and Culbertson, 1992a; Spangler and 
Culbertson, 1992b). Indications for splenectomy in cats include systemic mastocytosis (Liska et al., 
1979) and splenic haemangiosarcoma (Scavelli et al., 1985). Thrombocytosis has been observed 
postoperatively in both conditions (Helfand, 1988).
In a retrospective study of reactive thrombocytosis in dogs and cats neoplasia was the most 
frequent underlying disorder (Hammer, 1991). However the use of chemotherapeutic agents may 
have contributed to the thrombocytosis in approximately half of these cases by causing rebound 
thrombocytosis after myelosuppression, or by the specific effect of vincristine, commonly used as 
part of the protocol (Hammer, 1991). When this is considered, gastrointestinal disease, mainly 
inflammatory in nature, was an important cause of reactive thrombocytosis (Hammer, 1991) (see 
Table 3.3). However, whether surgical diagnostic procedures could have contributed to the 
thrombocytosis in these cases is not made clear in the study.
Moderate doses of vincristine are thought to increase platelet count through stimulation of 
thrombopoiesis (Bithell, 1993h; Mackin et al., 1995), although low doses, which result in a prompt 
transient thrombocytosis have been proposed to induce megakaryocyte fragmentation (Mackin et 
al., 1995). Vincristine binds to the platelet microtubule cytoskeleton and may lead to concealment of 
platelets from the thrombopoietic regulatory system or lead to subtle disruption of platelet 
precursors inducing release of thrombopoietic factors (Mackin etal., 1995). *
* The increase in platelet count seen with the use of vincristine in ITP, however, is unlikely to be due to 
accelerated thrombopoiesis, which is already maximal. It is more likely to be attributable to decreased platelet 
destruction induced by vincristine. Proposed mechanisms include impairment of the monocyte-macrophage 
phagocytic system, reduced synthesis of antiplatelet antibodies and decreased antibody-platelet binding 
(Mackin etal. 1995).
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gastrointestinal diseases pancreatitis
19% of cases chronic hepatitis
gingivitis/periodontitis
colitis
inflammatory bowel disease 
gastric ulceration
neoplasia
in absence of chemotherapy
13% of cases
neoplasia
with concurrent chemotherapy
12% of cases
lymphoma
melanoma
nasal adenocarcinoma 
primary CNS tumours 
mast cell tumour 
mesothelioma
endocrine diseases
10% of cases
other diseases
46% of cases
diabetes mellitus
hyperadrenocorticism
hypothyroidism
Table 3.3 The most common causes of reactive thrombocytosis in dogs and cats (Hammer,
1991).
3.3.3. Autonomous thrombocytosis or thrombocythaemia
Autonomous thrombocytosis is called thrombocythaemia (also known as essential, primary, 
haemorrhagic or idiopathic thrombocythaemia) (Bithell, 1993h). It is an uncommon disorder in 
humans (Bithell, 1993h), and there is a single report of its occurrence in a cat (Hammer et ai.,
1990). Thought to be a clonal neoplasm, there is an increase in megakaryocyte number, mass and 
mean megakaryocyte volume, with subsequent increases in platelet count (Bithell, 1993h). Platelet 
counts are typically massively increased (greater than 1000 x 109/L) (Bithell, 1993h) and in the one 
cat reported ranged between 1 660 and 3 000 x 109/L (Hammer et al., 1990). Striking abnormalities 
in platelet size, shape and structure are commonly seen in human cases, and MPV is usually 
increased (Bithell, 1993h). Clinical signs of haemorrhage and thrombosis occur in humans and may 
reflect intrinsic defects in platelet function and hyperaggregability (Bithell, 1993h). Severe 
gastrointestinal haemorrhage was a feature in the reported cat, but no evidence of thrombosis was 
found on necropsy (Hammer et al., 1990). Concurrent anaemia may occur in humans and is 
thought to be due to iron deficiency of chronic blood loss (Bithell, 1993h). In addition there is 
leukocytosis and splenomegaly in most cases (Bithell, 1993h).
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Other myeloproliferative disorders in humans such as polycythemia vera, chronic myelocytic 
leukaemia and myelofibrosis can result in thrombocytosis (Bithell, 1993h). Thrombocytosis has 
been associated with megakaryocytic myelosis and acute megakaryoblastic leukaemia in a cats 
(Michel et al., 1976; Colbatzky and Hermanns, 1993), and with myelofibrosis in dogs (Hoff et al.,
1991). Thrombocytosis does not appear to be a common clinical feature of feline polycythemia 
vera, though this is an uncommon disease in the cat. Of 32 cats reported with the disease (Reed et 
al., 1970; Foster and Lothrop, 1988; Swinney et al., 1992; Evans and Caylor, 1995; Hasler and 
Giger, 1996), only one had a platelet count above the reference range (Swinney et al., 1992).
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4. P revalence  o f Lo w  A utom ated  P la telet  C ounts  in C a ts : 
C om parison  w ith  Prevalence  of T hro m bo cyto penia  Based  on 
Blo o d  S mear-E stim ation
4.1 In troductio n
Thrombocytopenia is uncommon in cats, with a reported prevalence of 1.2% of 3300 cats admitted 
to a veterinary teaching hospital (Jordan etal., 1993). In only 0.42% (14 cases) were clinical signs 
of abnormal haemostasis detected (Jordan et al., 1993). However, laboratory results suggesting 
thrombocytopenia are a common finding when automated cell counters are used. Impedance 
counters differentiate cells by size alone. However, in cats, red blood cells and platelets overlap in 
size and hence settings which exclude the red cells from the platelet count, will also exclude a 
proportion of platelets. An additional problem is caused by in vitro aggregation of platelets, which 
appears to occur readily and frequently in feline blood (Jain, 1986b; Thrall and Weiser, 1992; 
Zelmanovic and Hetherington, 1998). Aggregation of platelets into large clumps may cause them 
to be counted as one large cell by impedance cell counters, underestimating the platelet count and 
falsely increasing the counts of other cell types. Falsely decreased platelet counts occur in laser 
cell counters as well, because platelet aggregates have a different light scatter pattern than do 
individual platelets and are not counted as platelets (Zelmanovic and Hetherington, 1998). 
Aggregation of platelets also interferes with all methods of manual counting.
The frequency of occurrence of low automated platelet counts in feline samples in a diagnostic 
laboratory setting has not been reported. Laboratory experience at the University of Glasgow 
Veterinary Haematology Laboratory suggested it was so common, that rarely could an automated 
platelet count be relied upon. This study was undertaken to retrospectively examine the 
prevalence of low automated platelet counts compared with low blood smear-estimated platelet 
counts in feline blood samples over a 12 month period in this laboratory.
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4.2 Materials  and  M ethods
The records of automated haematology counts for all feline blood samples undergoing full blood 
count received by the University of Glasgow Veterinary Haematology Laboratory were 
retrospectively examined for the period from 1/4/97 to 31/3/98. Data were collected from the 
records, and if necessary, by examination of stored blood films from each sample. When an 
individual cat was sampled on more than one occasion, the results from the first blood sample 
were included in the study.
Blood was submitted in EDTA for haematological analysis, using any one of a variety of 
commercially available EDTA tubes. Samples collected from patients hospitalised at the 
University of Glasgow Veterinary Hospital (internal samples) were stored at room temperature until 
analysed within 24 hours (in most cases within 8 hours). Samples also were received from 
veterinarians elsewhere by first class mail (external samples) and were held at room temperature 
until analysed on the day of receipt. If clots were seen, or there was grossly inadequate filling of 
the EDTA tube, such that a disproportionately high concentration of EDTA would be present, this 
was noted and these samples were excluded from the data in this study.
After thorough mixing of the blood samples on an automated mixer for 10 minutes, a full 
automated blood count was performed on each sample using an impedance cell counter (Minos® 
Vet, Abx Hematologie, Montpellier, France) which was maintained and calibrated as 
recommended by the manufacturer. A full white blood cell differential and smear cytological 
analysis also was performed on each sample. Thin air dried blood smears made after thorough 
mixing of the sample were stained with a modified May-Grunwald-Giemsa stain and examined 
under light microscopy. Platelet numbers were reported to be adequate, either because 
aggregates were seen or, subjectively, based on the experience of the laboratory technicians. 
Where the record did not note the results of smear evaluation for platelets, the slides were 
reexamined by the author for the presence of platelet aggregates. If no aggregates were found, an 
estimation of platelet count was made by averaging the number of platelets seen in 5 oil fields in 
the thin monolayer part of the smear. An Olympus BX50 microscope was used with a 100x oil 
lens, and an ocular with a field number of 22. Mean platelet numbers per oil field were multiplied 
by a factor of 15.8 to give an approximate count x 109/l (Tasker et al., 1999; Tasker and Mackin, 
1999).Thrombocytopenia was defined as a platelet count of less than 200 x 109/l.
Statistical analyses were performed using Minitab for Windows software (release 10.2, 1994, 
Minitab Inc., State College, PA). All counts were log transformed and comparisons were made 
using an unpaired t test. A P value of < 0.05 was considered significant.
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4.3 R esults
A total of 583 feline blood samples were submitted during this period. Of these the records were 
incomplete in 14 cases for various reasons including cancellation of the request by the submitting 
veterinarian. In another 4 samples significant underfilling of the EDTA tube was noted and in 26 
samples gross clotting of the sample had occurred, making them unsuitable for further analysis. 
These samples were excluded from further study leaving a total of 539 samples from 359 cats, 
comprising 325 internal samples from 227 cats and 214 external samples from 132 cats.
In 256 of 359 cats sampled (71%) the automated platelet counts were indicative of 
thrombocytopenia (< 200 x 109/l) (Figure 4.1). In 43 of 359 cats (12%) platelet counts were 
severely decreased (< 50 x 109/l) and in 7 of 359 cats (1.9%) were < 20 x 109/l. Based on 
evaluation of smears, 11 of 359 cats (3.1%) had platelet counts of < 200 x 109/l. Platelet counts 
were markedly decreased (<50 x 109/l) in 9 of 359 cats (2.5%) and in 8 of 359 cats (2.2%) were < 
20 x 109/l. In all samples with blood smear-estimated thrombocytopenia, the automated platelet 
count was < 200 x 109/l. In only 4 of the 11 samples, was thrombocytopenia noted in the 
haematology report to the submitting veterinarian.
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Figure 4.1 Frequency distribution of automated platelet counts from 359 cats during a one year 
period.
Of the 11 samples with blood smear-estimated thrombocytopenia, 4 cats had histories recorded 
that suggested a haemostatic defect was present. In all 4 of these cats the platelet count based on 
both automated count and smear evaluation was < 20 x 109/l. One of these 4 cats had pemphigus 
foliaceus and was being treated with myelosuppressive drugs, one had feline immunodeficiency 
virus-related disease and in 2 cats an underlying disease was not reported. Of the remaining 7
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thrombocytopenic samples, one was from a cat during chemotherapy for lymphosarcoma, one cat 
had renal neoplasia, one had haemobartonellosis, one had hepatic disease and a positive feline 
coronaviral titre, and one had intracranial disease of suspected nutritional origin. In two cats no 
underlying disease was reported.
When external samples were compared with internal samples, there was no significant difference 
(P = 0.23) in the automated platelet counts.
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4.4 D iscussio n
Thrombocytopenia as evidenced by smear examination was present in only 3.1% of cats. Jordan 
et al. (1993) reported a prevalence of thrombocytopenia of 1.2%. These figures are broadly similar 
and differences are likely to be due to sampling errors. The study by Jordan et al. (1993) used a 
much larger sample taken over a 5 year period and, in addition, where haemocytometer counts 
were not performed, the average of platelet counts in 25 oil fields was used to estimate platelet 
numbers. This is a much greater number of fields counted than in the present study, and would 
lessen any inaccuracy resulting from uneven distribution of platelets on the blood smear.
As has been previously reported, neoplasia and infectious diseases are the most common 
diseases found in cats with thrombocytopenia (Jordan et al., 1993). In some cats, 
thrombocytopenia may represent a component of disseminated intravascular coagulation (DIC) 
because 38% of cats undergoing coagulation testing have been found to meet some or all of the 
diagnostic criteria for DIC (Peterson et al., 1995). No cases of immune mediated 
thrombocytopenia were diagnosed during this one year survey, in keeping with the low prevalence 
of this disease in cats (Jordan etal., 1993; Peterson etal., 1995).
Automated platelet counts by use of an impedance counter were low in the majority of cats 
sampled (71%), whereas the prevalence of thrombocytopenia based on blood smear-estimation 
was 3.1%. Thus apparent thrombocytopenia represented a significant problem in automated 
counts with this impedance cell counter. Although the automated counts were low in all cats with 
blood smear-estimated thrombocytopenia, the frequent occurrence of falsely low automated 
platelet counts meant that the presence of thrombocytopenia commonly was ignored.
The impedance counting method, in which platelets and red cells are differentiated by size alone, 
contributes to falsely low automated platelet counts in cats. In the Minos® Vet analyser, red cells 
and platelets are analysed concurrently in one channel with a 50 pm-diameter aperture. The 
impedance generated by each particle passing through the sensing zone is plotted against the 
number of impulses (particles) for analysis. A fixed upper platelet and lower RBC threshold of 17.5 
fL for cats has been determined by the manufacturer. In comparison, a threshold of 27 fL is used 
for dogs. In most cases this threshold cuts the histogram at the trough between the platelets and 
red cells. However the platelet and red cell histograms are commonly overlapping in cats and this 
threshold may exclude a proportion of the larger platelets from the platelet count and a proportion 
of the smaller red cells from the red cell count. Feline platelets are larger than those of other 
species, with a mean volume of 11.0 to 18.1 fl (Weiser and Kociba, 1984). Mean platelet volume 
of dogs, pigs and human beings is 7.6-8.3 fl (Jain, 1986c). The magnitude of error in measuring 
platelet count is much greater than for red cell count because of the difference in relative numbers 
of platelets and RBCs. Aggregation of platelets increases this effect because the clumped platelets
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appear to the cell counter as one larger cell. Although other factors such as red cell microcytosis 
and schistocytosis will also contribute to this problem, platelet aggregation is a far more frequent 
occurrence, occurring in at least 50% of feline blood samples analysed during this one year period. 
Platelet aggregation occurred in 66.6% of blood samples collected from 48 healthy, anaesthetised 
cats (Zelmanovic and Hetherington, 1998), and in another study, aggregation induced interference 
was found in 56% of 41 feline blood samples undergoing automated cell counting (Byrne et al.,
1994).
The use of optical cell counters in which platelets and red cells are differentiated by their light 
scattering pattern would be expected to avoid these errors. However the light scattering pattern of 
a platelet aggregate is not the same as that of a single platelet and hence aggregates are 
excluded from the platelet count (Zelmanovic and Hetherington, 1998). Manual counting of 
platelets is also affected by aggregation since individual platelets cannot be counted within 
aggregates either on smears or in a haemocytometer. The presence of aggregation is likely to lead 
to uneven distribution of platelets with aggregates accumulating on the edges of smears and 
counting chambers. Hence aggregation of feline platelets in vitro contributes largely to technical 
difficulties of platelet counting and accurate counting of feline platelets depends on its absence.
Platelets are reactive cells which can be stimulated to aggregate by a variety of factors including 
substances released from activated platelets themselves, such as adenosine diphosphate (ADP) 
and serotonin, circulating substances such as adrenalin and vasopressin, extravascular 
substances such as collagen, products of coagulation cascade such as thrombin, physical factors 
such as shear stress and stirring, and many foreign substances (Tschopp, 1969; Tuffin, 1991; 
Scrutton and Athayde, 1991; Brass, 1991; Chow et al., 1992; McNicol et al., 1993). Certain 
features of feline platelets may result in them being more reactive than those of other species: 
their larger size (Jain, 1986c), higher concentration of serotonin (Jain, 1986c) and, uniquely among 
domesticated species, response to serotonin by irreversible platelet aggregation with granule 
release (Poole, 1996). Irreversible aggregation occurs at lower concentrations of ADP in cat 
platelets than in other species (MacMillan and Sim, 1970). The small size and imperfectly tractable 
nature of cats contributes to difficulties in venipuncture which may increase the likelihood of in 
vitro platelet aggregation. Gentle handling of the sample, avoidance of the use of small bore 
needles for venipuncture and undue negative pressure on the syringe (Poole, 1996), use of 
siliconised glassware or plastic sample containers (Davenport et al., 1982; McNicol, 1996), and 
discarding of the first few drops of the sample (McNicol, 1996), have been advocated to reduce 
aggregation formation. However the problem appears to be unavoidable even in favourable 
conditions such as under anaesthesia. A simple method to consistently avoid platelet aggregation 
in cats would be valuable. No significant contribution to platelet aggregation could be attributed to 
delays and additional handling arising from sample mailing, in this study, with no significant 
difference (P > 0.05) in automated platelet counts between external samples and internal samples.
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The findings of this survey demonstrate that while thrombocytopenia is an uncommon occurrence 
in cats, apparent thrombocytopenia resulting from inability of an impedance counter to accurately 
quantify platelet counts in feline blood samples is common. This necessitates examination of 
individual blood smears for the presence of adequate platelet numbers, and vigilance on the part 
of laboratory workers for the few cats in which thrombocytopenia is actually present. In this study, 
as is previously reported, thrombocytopenia in cats is most commonly associated with neoplasia, 
chemotherapy, and infectious diseases.
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5. Evaluation  of a  C itrate  Based  A ntico ag ulant  w ith  P l a t e l e t  
In h ib ito r y  A ctivity  fo r  Feline  B lo o d  C ounts
S.1. Introductio n
Aggregation of platelets in feline blood samples results in difficulty assessing platelet number by all 
laboratory means in the majority of feline blood samples (Chapter 4). A citrate based anticoagulant 
has been developed for use in platelet studies and heparin assays in human patients. CTAD 
anticoagulant (Diatube-H) contains citrate, theophylline, adenosine and dipyridamole, and is 
available commercially as 5 ml Vacutainers® (Becton Dickinson, Oxford, UK). The platelet inhibitors 
in CTAD inhibit platelet activation by maintaining a high intracellular cyclic adenosine 
monophosphate (cAMP) concentration. Theophylline and dipyridamole inhibit phosphodiesterase 
degradation of cAMP. Adenosine activates adenyl cyclase, which catalyzes cAMP production from 
ATP. Dipyridamole prevents uptake of adenosine by red blood cells, and thus a synergistic 
response is seen when these compounds are combined (Contant et al., 1983; Narayanan, 1995). 
Cyclic AMP keeps platelets in a resting state by regulating the sequestration of calcium in 
intracytoplasmic organelles (Vermylen and Deckmyn, 1993).
The use of this combination of platelet inhibitors to prevent platelet activation in vitro has not been 
reported previously in cats. However, addition of prostaglandin Ei (PGEi), an adenyl cyclase 
activator, to citrate anticoagulant, resulted in significant reduction in feline platelet aggregatory 
responses to agonists, and reduction in the occurrence of spontaneous platelet aggregation (Welles 
et al., 1994b). The purpose of this study was to evaluate the use of CTAD in feline haematology, 
with assessment of its effects on platelet aggregation and any artifacts created in other cells .
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5.2. Ma ter ia ls  and  M ethods
Aliquots of a commercially available anticoagulant (CTAD) were withdrawn from Vacutainer® 
collection tubes and used to make up smaller, 1 ml sample tubes. CTAD tubes contain 0.109 M 
citric acid, 15 mM theophylline, 3.7 mM adenosine, and 0.198 mM dipyridamole with pH adjusted to
5.4. To 1 ml plastic blood collection tubes which contained no anticoagulant, 105 pi of either CTAD 
or a solution of 32 g/l of trisodium citrate was added. A fill line marked at 1050 pi to give a 9:1 ratio 
of blood to anticoagulant. Total sample volume of 1050 pi was chosen because a reference mark 
was already present on the tubes at this point. Tubes were labelled and color coded for ease of 
identification. Commercially available 1 ml tubes containing potassium EDTA were used.
Blood samples were obtained from cats undergoing blood collection for routine haematology for 
investigation or monitoring of various diseases at the University of Glasgow Veterinary Hospital. 
Cats were not selected on the basis of their illness. From each cat, a blood sample collected via 
jugular venipuncture with a needle and syringe was divided into preprepared CTAD tubes, EDTA 
and/or citrate tubes. Blood samples were obtained under normal clinical conditions by different 
operators of varying experience, from cats of differing tractability, and therefore a single clean 
venipuncture was not always possible. Needle size and syringe size were not standardised. Most 
samples were obtained without sedation or anaesthesia.
The blood samples from each cat were stored at room temperature until analysis on the same day, 
usually within 4 hours, at the University of Glasgow Veterinary Haematology Laboratory. Notation 
was made of inadequate filling of sample tubes or if clots were seen in samples. These samples 
were excluded from the study. After mechanical mixing for 10 minutes, a blood smear was 
prepared from each sample, and a full automated blood count was performed which included 
determination of red blood cell count, haemoglobin concentration, haematocrit, MCV, MCH, MCHC, 
total white cell count, platelet count, mean platelet volume (MPV), “platelet-crit" and platelet 
distribution width (PDW). An impedance cell counter (Minos® Vet, Abx Hematologie, Montpellier, 
France) was used. It was maintained and calibrated as recommended by the manufacturer.
White blood cell differential and smear cytological analysis were performed on each sample by 
laboratory technical staff. Air dried blood smears, stained with a modified May-Griinwald-Giemsa 
stain, were examined under light microscopy by the author in a blinded manner for the degree of 
platelet aggregation. A score was given as follows: aggregates of 30 or more platelets present = 5, 
aggregates of 20-30 platelets = 4, aggregates of 10-20 platelets = 3, aggregates of 4-8 platelets = 
2, few aggregates of 2-4 platelets only = 1, no aggregates found = 0. An estimation of platelet count 
was made by averaging the number of platelets seen in 10 oil fields in the thin monolayer part of the 
smear. An Olympus BX50 microscope was used with a 100x oil objective, and an ocular with a field 
number of 22. Mean platelet numbers per oil field were multiplied by a factor of 15.8 to give an 
approximate count x 109/l (Tasker et al., 1999; Tasker and Mackin, 1999).
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Haemocytometer platelet and white blood cell counts were performed on the same day by 
laboratory technical staff using standard methods. Blood was diluted 1:100 for platelet counting with 
1% formalin in 32 g/1 trisodium citrate and the number of platelets in five 0.2 x 0.2mm squares were 
counted. The count was then divided by the volume counted (0.004 x 5 x lO-6!) and multiplied by the 
dilution factor (100) to give total platelet count per litre. For white cell counting, blood was diluted 1 
in 20 with 2% acetic acid coloured pale violet with gentian violet and the number of white cells in 
four 1mm2 squares were counted. The count was then divided by the volume counted (0.1 x 4 x 10' 
6I) and multiplied by the dilution factor (20) to give total white cell count per litre. In both techniques, 
the average count of the two sides of the haemocytometer chamber was recorded.
All counts performed in CTAD or citrate were multiplied by a factor of 1.11 to correct for dilution 
(MCV, MCH, MCHC, MPV and PDW were not corrected). The difference in values being compared 
were plotted against their mean. The mean of the difference and the standard deviation of the 
difference ( s difr) were calculated for assessment of agreement between methods (Bland and 
Altman, 1986). Statistical analyses were performed using Minitab for Windows software (release 
10.2,1994, Minitab Inc., State College, PA). All counts were log transformed and comparisons were 
made using a Wilcoxon test. A P value of < 0.05 was considered significant.
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5.3. Results
Samples were collected from 55 cats but only 51 samples were included in the study. Gross clotting 
was observed in one citrate sample which was excluded from study but was not observed in any 
EDTA or CTAD anticoagulated sample. Three other samples were excluded from study because of 
incorrect filling of blood tubes. In the remaining samples, blood was collected into EDTA and CTAD 
tubes in 39 cases and into EDTA, CTAD and citrate tubes in 12 cases.
In 36 of 51 (71%) EDTA samples automated platelet counts were less than 200 x 109/l. In 16 (31%) 
samples the platelet count was less than 100 x 109/l and in 3 (6%) samples it was less than 50 x 
109/l. In comparison, in only 12 of 51 (24%) CTAD samples, the automated platelet count was less 
than 200 x 109/l and one was less than 100 x 109/l but greater than 50 x 109/1. In 6 of 12 (50%) 
citrated samples the automated platelet count was less than 200 x 109/l, in 2 (17%) samples platelet 
counts were less than 100 x 109/l and in one (8%) sample platelet count was less than 50 x 109/l. 
An example of the platelet volume distribution curve produced by the impedance counter is shown 
in Figure 5.1.
Automated platelet counts were higher in CTAD samples than in their EDTA pairs in 49 of 51 (96%) 
samples (Figure 5.2). Automated platelet counts were higher in citrate samples than in their EDTA 
pairs in 10 of 12 (83%) samples. The agreement between automated platelet counts in CTAD 
samples and their citrate pairs was close for 11 of 12 (92%) samples, however a bias was apparent 
with the counts being higher in CTAD samples than in their citrate pairs in 11 (92%) of the samples 
and exactly the same in one of 12.
Platelet counts were significantly higher (P £ 0.001) in samples containing CTAD, than in samples 
containing EDTA . This relationship persisted whether platelet numbers were assessed by 
impedance counter, haemocytometer or smear estimation. Mean (± sd) automated platelet count in 
EDTA was 178 (± 131) x 109/l compared with a mean of 316 (± 153) x 109/1 in CTAD. On 
examination of smears, platelet aggregation appeared less severe in 45 of 51 (88%) CTAD 
samples when compared with their corresponding EDTA sample (Figure 5.3), and the difference in 
aggregation grade of samples between the two anticoagulants was significant (P < 0.001). The 
mean differences ± are tabulated in Table 5.1.
No significant difference (P > 0.05) was found between citrate and EDTA anticoagulated samples 
with respect to either automated platelet counts, smear estimates of platelet counts or aggregation 
grades. For the 12 samples which included a citrated sample, the mean (± sd) automated platelet 
count in EDTA was 153 (± 79) x 109/l compared with a mean of 213 (± 109) x 109/l in citrate. 
Significantly higher automated platelet counts (P = 0.004) and smear estimates of platelet counts (P 
= 0.045) were found in CTAD samples than their corresponding citrate pairs, and aggregation 
grades were significantly lower (P = 0.014) in CTAD than in citrate. Platelet aggregation grade was
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lower in CTAD samples than in their citrate pairs in 8 of 12 (66%) samples and exactly the same in 
the remainder (Figure 5.3).
The mean differences (± s djfr) of white cell counts are tabulated in Table 5.1. Automated total white 
cell counts in EDTA were significantly higher (P < 0.001) than those performed in CTAD; however, 
when white cell counts were performed by haemocytometer, there was no significant difference (P = 
0.258) between EDTA and CTAD anticoagulated samples (Figure 5.4). In samples for which all 
three were available (n = 30), the mean (± sd) automated EDTA white cell count was 17.2 (± 7.1) x 
109/l, while the mean haemocytometer EDTA white cell count was 12.0 (± 5.7) x 109/l and the mean 
automated CTAD white cell count was 12.7 (± 6.2) x 109/l. However haemocytometer white cell 
counts in EDTA and automated white cell counts in CTAD were significantly different (p = 0.008). In 
14 of the 30 cat blood samples the automated EDTA white cell count was higher than the reference 
interval (>15.5 x 109/l); however, in 8 of these, both the haemocytometer EDTA and automated 
CTAD white cell counts were less than 15.5 x 109/l. In only one case was the automated CTAD 
white cell count above the reference range while the haemocytometer EDTA white cell count was 
not.
Automated red cell counts in CTAD were significantly different (P < 0.001) when compared with 
EDTA anticoagulated samples, however the difference was small. The mean (± sd) automated 
EDTA red cell count was 7.84 (± 1.93) x 1012/l compared with a mean of 8.08 (± 1.97) x 1012/l in 
CTAD. This was accompanied by a significant difference in MCV between EDTA and CTAD 
anticoagulated samples, with the mean (± sd) MCV of 42.7 (± 4.3) fl in EDTA samples compared 
with a mean of 40.9 (± 4.0) fl in CTAD samples (P < 0.001). MCV was also significantly lower (P = 
0.009) in citrate samples than in EDTA anticoagulated samples. The mean differences (± sdiff) are 
tabulated in Table 5.1.
Mean platelet volume was significantly lower in CTAD anticoagulated samples compared with 
EDTA (P < 0.001), mean (± sd) value of 10.5 (± 1.1) fl in EDTA and mean of 10.2 (± 1.0) fl in 
CTAD. Similarly, MPV of citrate anticoagulated samples was significantly lower (P = 0.008) than 
EDTA anticoagulated samples, but did not differ significantly (P = 1.000) from CTAD samples. The 
platelet-crit was significantly higher in CTAD samples than in EDTA (P < 0.001), mean (± sd) of 
0.194 (± 0.167) I/I in EDTA and mean of 0.325 (± 0.184) l/l in CTAD. The mean differences (± Sdiff) 
are tabulated in Table 5.1.
No difference in cell morphology or staining characteristics was seen with any of the anticoagulants.
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Table 5.1 Mean differences and standard deviations of the differences (sdiff) for various 
parameters comparing anticoagulants and techniques. Mean differences approach zero as the 
agreement between methods of analysis increases, n = number of paired samples for comparison.
parameter and technique anticoagulant n mean
difference
Sdlff
automated platelet count 
(x 109/l)
CTAD - EDTA 51 137.7 113.6
citrate - EDTA 12 59.7 100.5
CTAD - citrate 12 73.4 172.8
hemocytometer platelet count 
(x 109/l)
CTAD - EDTA 16 187.3 203.0
smear estimate of platelet count 
(x 109/l)
CTAD - EDTA 51 404.3 358.3
citrate - EDTA 12 202.5 299.9
CTAD - citrate 12 227.6 522.5
platelet aggregation grade
CTAD - EDTA 51 -2.47 2.02
citrate - EDTA 12 -0.83 2.33
CTAD - citrate 12 -2.50 2.02
MPV (fl)
CTAD - EDTA 51 -0.32 0.56
citrate - EDTA 11 -0.62 0.48
CTAD - citrate 11 0.07 0.46
platelet-crit (I/I)
CTAD - EDTA 51 0.131 0.110
citrate - EDTA 11 0.025 0.015
CTAD - citrate 11 -0.064 0.088
total white cell count 
(x 109/l)
automated CTAD - 
automated EDTA
51 -3.26 3.61
automated EDTA - 
hemocytometer EDTA
30 5.15 3.90
automated CTAD - 
hemocytometer EDTA
30 0.66 2.92
automated CTAD - 
hemocytometer CTAD
18 0.10 1.63
RBC (x 1012/l)
CTAD - EDTA 51 0.23 0.29
citrate - EDTA 12 0.06 0.17
CTAD - citrate 12 0.13 0.20
MCV (fl)
CTAD - EDTA 51 -1.71 1.54
citrate - EDTA 12 -1.17 0.83
CTAD - citrate 12 -0.33 0.78
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5.4. D iscussion
Regardless of the laboratory method used for assessment, platelet counts were higher when CTAD 
was used as an anticoagulant compared with the more traditionally used EDTA. In many cases the 
difference in platelet counts was clinically relevant. Whereas one third of cats had platelet counts 
apparently low enough to indicate potentially important thrombocytopenic disease (<100 x 109/l) in 
EDTA anticoagulated samples, all but one had platelet counts over 100 x 109/l in CTAD. Decrease 
in the subjective degree of platelet aggregation in CTAD samples suggests that the improvement in 
platelet counts was a result of decreased platelet aggregation. Significant reductions in human 
platelet activation have been demonstrated by use of CTAD instead of EDTA. The proportion of 
activated platelets increases progressively with time in human blood collected in EDTA as 
measured by expression of membrane glycoproteins which accompany platelet activation. They 
reach over 30% by 4 hours and 79% at 48 hours. However in blood collected into CTAD, the 
percentage of activated platelets increases from 7.5% at 4 hours to 10.2% at 24 hours and 16% at 
48 hours (Kuhne ef a/., 1995).
Citrate anticoagulant may itself offer some advantages over EDTA. In another study severe platelet 
aggregation was seen less frequently in feline blood samples when anticoagulated with citrate, than 
when anticoagulated with EDTA (Morittz and Hoffmann, 1997). When held at 37 °C, 94% of citrated 
canine platelets retained their smooth discoid shape after half an hour, whereas only 34% of EDTA 
platelets retained this shape under the same conditions. 55% of EDTA platelets developed 
pseudopods and 11% developed both pseudopods and underwent a change in shape from discs to 
spheres (Handagama et a/., 1986). This difference in effect between the two anticoagulants 
persisted over time and at different storage temperatures. The mechanism for this effect of EDTA 
on platelets has not been established. Development of pseudopods and spherical transformation 
are early morphological changes associated with activation of platelets due to reorganisation of the 
cytoskeletal actin filamentous network (Tuffin, 1991). Hence, it is likely that EDTA itself leads to a 
degree of platelet activation by mechanisms unknown. Examination of Figure 5.2b reveals a 
positive bias with most samples having higher automated platelet counts in citrate than in EDTA. 
This trend is also apparent in the smear estimated platelet counts (not shown), however is only 
slightly apparent in the subjective assessment of platelet aggregation grade (Figure 5.3.b), in which 
almost equal numbers of samples have more platelet aggregation in citrate than in EDTA (n = 3) or 
equal degrees of aggregation (n = 4) as have less platelet aggregation in citrate than in EDTA (n = 
5). While no significant differences were found in platelet counts or aggregation scores between 
EDTA and citrate samples, the possibility that citrate is in fact, associated with less platelet 
activation than EDTA cannot be rejected because of the low power of the study.
Figure 5.2.C shows that in most samples the automated platelet counts in citrate and CTAD were in 
close agreement and although there is a statistically significant difference between automated 
platelet counts in the two anticoagulants, in most samples the difference is unlikely to be clinically 
relevant. However a consistent bias is seen in Figure 5.2.c with CTAD counts tending to be higher
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than those in citrate, and a similar pattern is seen in the smear estimates of platelet count (data not 
shown). Accordingly, the subjective degree of platelet aggregation was less in CTAD than in citrate 
as shown by Figure 5.3.c. Although the presence of the outlying citrate result in Figure 5.2.c 
enlarges the mean difference between the two anticoagulants and influences the statistical 
conclusions, when this result is removed from the data set, automated counts remain statistically 
significantly higher and aggregation grades remain significantly lower in CTAD anticoagulant than in 
citrate. In addition, neither gross clotting, nor severe aggregation rendering the platelet count very 
low, occurred in CTAD samples during the study, but each occurred once in citrate samples. These 
findings suggest that the platelet inhibitory properties of CTAD are of clinical relevance and confer 
an additional advantage to the use of citrate alone in feline blood samples. However further study of 
a larger number of samples would be desirable to confirm the trends seen here.
A difference between citrate anticoagulant and CTAD is predicted from the actions of the platelet 
inhibitory constituents of CTAD. The use of CTAD solution resulted in significantly less human 
platelet activation than citrate solution alone as measured by the degree of heparin inactivation by 
released platelet factors (Contant et al., 1983). In studies of feline platelets using PGE1t which also 
increases platelet cAMP, Welles et al. (1994b) found that spontaneous aggregation of feline 
platelets never occurred in blood samples collected in citrate with added PGE1( and the platelets 
became nonreactive to aggregatory agonists whereas aggregation was observed when citrate alone 
was used. However species variations have been found in the action of various inhibitors of platelet 
aggregation. Low concentrations of adenosine which inhibit ADP-induced aggregation of human 
and rabbit platelets do not inhibit feline platelets (Philp and Bishop, 1970). However the 
concentration of adenosine in CTAD is high, and falls within the range at which inhibition of feline 
platelet aggregation by adenosine begins to be seen (Tschopp, 1969). Dipyridamole, at 
concentrations higher than those present in CTAD did not inhibit ADP-induced platelet aggregation 
in cats (Philp and Bishop, 1970). The relevance of these differences in inhibition of ADP-induced 
aggregation is unknown. Although ADP has been proposed as a principal nucleotide inducing 
aggregation in physiological situations (Mustard and Packham, 1970), platelet activation during 
stirring has been attributed to serotonin as opposed to ADP in the cat (Tschopp, 1969), and hence 
serotonin may be an important agonist during handling of feline blood samples. Serotonin-induced 
feline platelet aggregation is inhibited by very low concentrations of adenosine (Tschopp, 1969). 
Theophylline has been shown to enhance the de-aggregatory action of prostacyclin (PGI2), an 
adenyl cyclase activator, in vivo in cats (Gryglewski et al., 1978).
Lower automated white cell counts were seen when CTAD was used compared with EDTA. The 
CTAD white cell counts closely approximated manual EDTA white cell counts in 30 cats in which 
both were performed, although there was a statistically significant difference between them (Figure 
5.4). Because the impedance type analyser differentiates cell types by size alone, white cell counts 
may be over-estimated when platelet aggregation is present because the size of platelet aggregates 
approximates that of white cells. The lower white cell counts in CTAD therefore would be expected
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to accompany the decrease in platelet aggregation found with this anticoagulant compared with 
EDTA. Concurrent falsely increased white cell counts (pseudoleukocytosis) and falsely decreased 
platelet counts (pseudothrombocytopenia) have been demonstrated in human blood samples in 
EDTA as a result of in vitro platelet aggregation (Savage, 1984; Schrezenmeier et al., 1995) and 
previously have been noted to occur in feline EDTA blood samples (Byrne et al., 1994; Mischke et 
al., 1995). The differences in white cell count were clinically relevant. Half of the cats with an 
automated EDTA white cell count above the reference interval had normal white cell numbers when 
manually counted and when an automated count was done on CTAD anticoagulated blood. The 
degree of change in platelet count and white cell count was poorly correlated (data not shown) 
which may be due to the fact that aggregation was not completely inhibited in all samples, 
combined with inaccuracies in the platelet counting method.
Changes were observed in red cell parameters with CTAD samples. Although statistically different, 
the increase in red cell count in CTAD samples is not clinically relevant. Mean red cell volume 
tended to be lower in both CTAD and citrate samples than in EDTA samples. Swelling of human red 
cells has been noted with storage at room temperature. Although this change occurs with all 
anticoagulants, it is greatest with EDTA (Dacie and Lewis, 1991b).
Mean platelet volume was higher in EDTA samples than in corresponding CTAD and citrate 
samples. Increased MPV detected by impedance counters has been demonstrated in human and 
canine platelets in EDTA but is not apparent in citrate based anticoagulants (Bull and Zucker, 1965; 
Holme and Murphy, 1980; Thompson et al., 1983; Handagama et al., 1986). This is attributed to 
EDTA induced platelet swelling; an increase in the fluid volume with little or no change in dry weight 
(Holme and Murphy, 1980), the mechanism for which has not been elucidated. Shape change of 
platelets from discoid to spherical, as occurs during activation, is also associated with an increase 
in MPV (Holme and Murphy, 1980) and hence any factor which prevents platelet activation may be 
expected to produce a lower MPV. In a recent study by Zelmanovic and Hetherington (1998) the 
MPV of unnaggregated platelets in feline EDTA blood samples was lower than the MPV of free, 
activated platelets in aggregated samples. Thus, it is likely that the platelet inhibitors in CTAD by 
reduction of platelet activation contributed to the lower MPV in these samples compared with the 
EDTA samples in this study. However, no statistically significant difference in MPV was found when 
the two citrate based anticoagulants were compared. Although the sample size is too small to be 
certain that a difference is unlikely, this suggests that it is the citrate base of the anticoagulant which 
leads to the change in MPV. The increase in platelet-crit in CTAD samples is an expected 
consequence of increased platelet count.
It is not possible to assess how close to the true platelet count the platelet counts in this study may 
be. In general, automated cell counts are associated with fewer errors than manual ones because a 
much higher number of cells are counted. The coefficient of variation for human platelet counting by 
haemocytometer is 8-10% and by automated methods is 3-4% (Dacie and Lewis, 1991c). However,
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platelet counts by all methods will be underestimated when platelet aggregation is present. 
Aggregation interferes with impedance counting by changing perceived cell size, and interferes with 
optical cell counting because aggregates have a different light scatter pattern than do individual 
platelets and are not counted as platelets (Zelmanovic and Hetherington, 1998). The 0.1 mm depth 
of a haemocytometer will exclude large platelet aggregates from the counting area, and clumps are 
often seen collecting at the edges of the cover glass. Smaller platelet clumps may be seen within 
the chamber, but the numbers of platelets within them may be impossible to accurately count. 
Platelet counts estimated from smears are made inaccurate because the distribution of platelets on 
the smear is not uniform, with clumps accumulating at the sides and the feathered edge of the 
smear (Tvedten, 1994b). and platelet numbers within aggregates cannot be counted accurately. 
The overlapping size of feline platelets and erythrocytes causes further inaccuracies in impedance 
counting. Optical cell counters, which differentiate platelets and red cells by their light scatter 
pattern, rather than by size alone do not have this difficulty. An automated platelet count performed 
on unaggregated blood by one of these analysers is likely to provide the closest to a true platelet 
count. It would be of great value to compare samples collected into CTAD anticoagulant with EDTA 
and citrate samples using an optical cell analyser. However one source of error that will always be 
present with CTAD is the dilutional effect of using a liquid anticoagulant. Furthermore, while it 
reduces feline platelet aggregation, CTAD does not prevent it completely and a more optimal 
combination of platelet inhibitory agents may be found in future.
In conclusion, the use of CTAD anticoagulant offers several advantages over EDTA and result from 
a reduction in platelet aggregation. Although similar results were often obtained, the use of CTAD 
anticoagulant was associated with less platelet aggregation than citrate. The platelet inhibitors 
dipyridamole, adenosine and theophylline are likely to be responsible for this effect. Clinically 
relevant improvements in the accuracy of platelet counts and white blood cell counts are seen with 
its use. There are no detectable effect on cell morphology or staining characteristics, and little effect 
on red cell parameters.
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Figure 5.1 (following Page) Example of the platelet volume distribution curves generated by 
impedance counter (Minos Vet, Abx Hematologie) for aliquots of blood from the same cat which 
were anticoagulated with three different anticoagulants: a) EDTA (platelet count 80 x 109A), b) 
citrate (platelet count 155 x 109/l prior to correction for dilution) and c) CTAD (platelet count 180 x 
109/l prior to correction for dilution). Particles larger than 17.5 fl are assumed to be erythrocytes and 
are not shown. Particles smaller than 2 fl are assumed to be debris and the remaining particles are 
assumed to be platelets.
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Figure 5.2 (following page) Difference between automated platelet counts in one of three 
anticoagulants [count in anticoagulant 1 - count in anticoagulant 2] plotted against average [(count 
in anticoagulant 1 + count in anticoagulant 2)/2J. The middle solid line represents the mean of the 
difference and the outer solid lines represent the upper and lower limits of agreement (± 2sdiff). The 
dashed line represents a difference of zero (ie: peifect agreement between the results in the two 
anticoagulants).
a) Difference against mean for CTAD and EDTA. Mean difference ± s ^ is  137.7 ±  113.6 x 109A
b) Difference against mean for citrate and EDTA. Mean difference ±  sdm is 59.7 ±100.5 x 109/l.
c) Difference against mean for CTAD and citrate. Mean difference ±  sdiff is 73.4 ±172.8 x 109/l.
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Figure 5.3 (following page) Difference between platelet aggregation grade in one of three 
anticoagulants [grade in anticoagulant 1 - grade in anticoagulant 2] plotted against average [(grade 
in anticoagulant 1 + grade in anticoagulant 2)/2]. The middle solid line represents the mean of the 
difference and the outer solid lines represent the upper and lower limits of agreement (± 2 The 
dashed line represents a difference of zero (ie: perfect agreement between the results in the two 
anticoagulants).
a) Difference against mean for CTAD and EDTA. Mean difference ±  is -2.47 ±  2.02.
b) Difference against mean for citrate and EDTA. Mean difference ±  sdlff is -0.83 ±  2.33.
c) Difference against mean for CTAD and citrate. Mean difference ±  sdlff is -2.50 ±  2.02.
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Figure 5.4 (following page) Difference between white cell counts by differing methods [count 1 - 
count 2] plotted against average [(count 1 + count 2)/2J. The middle solid line represents the mean 
of the difference and the outer solid lines represent the upper and lower limits of agreement (± 2 
Sour)- The dashed line represents a difference of zero (ie: perfect agreement between the two 
counts).
a) Difference against mean for automated white cell counts in CTAD anticoagulant and EDTA. For 
most samples the white cell count is lower in CTAD anticoagulant than in EDTA by a mean ±  
sdtff of 3.26 ±3.61 x 1(fA In some samples white cell count in CTAD was as much as 8-12 x 
1(f/l less than in EDTA.
b) Difference against mean for automated white cell count and haemocytometer white cell count in 
EDTA. In almost all the EDTA samples the automated white cell count is much greater than the 
haemocytometer white cell count. Mean difference ±  sdlff is 5.15 ±3.90 x 109A
c) Difference against mean for automated white cell count in CTAD anticoagulant and 
haemocytometer white cell count in EDTA. There is close agreement between the automated 
white cell count in CTAD anticoagulant and the haemocytometer white cell count in EDTA for 
most samples. Mean difference ± s dtfr is 0.66 ±2.92 x 1(f/l).
d) Difference against mean for automated white cell count and haemocytometer white cell count in
CTAD. There is close agreement between the automated white cell count and haemocytometer 
white cell count in CTAD. Mean difference ± sdifr is 0.10 ±1.63 x 109/l).
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6. D isc u ssio n
The difficulties in laboratory evaluation of platelet number have inhibited the accurate study of 
disorders of platelet number in the cat. Quoted reference ranges for platelet numbers may be 
inaccurate. The thrombocyte response in various disease states has not been well defined and is 
frequently extrapolated from the human literature.
Disorders of platelet number are infrequently recognised in the cat, and they are unlikely to 
represent an important primary disease. The prevalence of thrombocytopenia in the cat is low, and 
associated spontaneous bleeding occurs even less frequently (Jordan et al., 1993), (Chapter 4). 
However, severe thrombocytopenia is an important and potentially life threatening clinical finding, of 
which the clinician needs to be aware. Unfortunately, thrombocytopenia may be frequently missed, 
as occurred in more than half of the cats with true thrombocytopenia as reported in Chapter 4, and 
this is likely to be due to the high frequency of false thrombocytopenia in the cat. The recognition of 
thrombocytosis in the cat is also hindered by the technical difficulties of feline platelet counting. 
Although the massive increases associated with essential thrombocythaemia should not escape 
detection, milder thrombocytosis may be obscured, with the loss of a potentially useful diagnostic 
marker for neoplastic or inflammatory disease.
An ideal method for platelet counting in the cat would fulfil the following criteria:
1. A small sample volume would be required (1-2 mL).
2. A large number of platelets would be counted to limit sampling errors.
3. Platelets would be accurately differentiated from other cell types and debris.
4. Aggregation of platelets would be prevented or reversed so that individual platelets could be 
counted, or a method for enumerating platelets within aggregates used.
5. The method would retain its accuracy after storage of blood samples for a reasonable period (24 
hours).
6. The method would not be unduly time consuming or expensive.
7. The method would enable counting of all blood cells and morphological examination from the 
same sample.
Automated cell counting is generally more accurate than manual counts because of the large 
numbers of cells counted (Kjeldsberg, 1993). in addition small sample volumes can be used, and 
the processing time for each sample minimised, allowing cost minimisation. Haematology analysers 
vary in their method of cell type determination, as reviewed in Chapter 2. Newer analysers using 
laser technology, are able to differentiate platelets from other cell types and debris with greater 
accuracy than older style impedance analysers. In addition, although platelets within aggregates 
cannot be counted, they are not mistaken for white cells (or other cell types) as occurs with
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impedance analysers (Chapter 5). However these analysers remain expensive and their use is 
limited to some veterinary laboratories.
Flagging of the presence of platelet aggregation is performed by many analysers but is of limited 
usefulness when the majority of samples are aggregated. The ability to estimate the number of 
platelets within an aggregate is inhibited by the variation is size of feline platelets, however 
assessment of platelet-crit rather than platelet number, may give a realistic reflection of the 
functional platelet mass. This may be a useful parameter since larger platelets are functionally 
more active than smaller ones, and hence it is the total volume of platelets present which 
determines the haemostatic potential.
The platelet-crit value determined by analysers such as the Minos is calculated from the platelet 
count and mean platelet volume and thus is prone to the same inaccuracies as the platelet count 
itself. However in some methods of analysis the platelet crit is actually measured. Using a method 
of differential separation of the buffy coat (quantitative buffy coat (QBC) analysis), measurement of 
the erythrocyte PCV, total WBC count and platelet count can be made in a similar manner to that 
used to measure PCV in a microhaematocrit tube. A cylindrical plastic float is used to expand the 
lengths of the buffy coat layers to allow their measurement. In a study of canine and feline samples, 
platelet aggregation caused more interference with the reference method (haemocytometer platelet 
counts) than with the QBC method (Levine et al., 1986). In another study of canine blood samples 
in which platelet aggregation was induced by the addition of ADP, the QBC platelet counts were 
minimally affected, whereas the platelet counts by impedance counter were decreased by a mean 
of 53% (Koplitz et al., 2000). However when platelet aggregation is severe, platelets clump on top of 
the QBC float and cannot be measured (Levine et al., 1986). Correlation of platelet counts 
calculated from platelet-crit with direct counts will be adversely affected by the variability in platelet 
size (platelet heterogeneity). However platelet-crit is a potentially more useful parameter, as 
previously mentioned.
Inaccuracies in platelet count caused by the presence of the float when platelets are aggregated are 
avoided by use of a centrifugal-based laser analyser, the VS2000 (HemaTechnologies Ltd, 
Glasgow, UK) which is still under development. In this analyser a laser is used to locate interfaces 
between air, plasma, platelets, white blood cells, red blood cells and the haematocrit seal and this 
allows accurate measurement of the lengths of the various layers without the use of a float to 
expand the buffy coat layers. However platelet aggregation also leads to falsely low platelet counts 
with this method as large platelet aggregates may be trapped amongst the red cell layer and not 
measured.
Overcoming the problem of platelet aggregation in feline blood samples would thus be a great aid to 
increasing the accuracy of feline platelet counts, by all methods developed to date. Although platelet 
aggregation may well begin as soon as the vein is punctured, the practicalities of sampling make
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this a difficult area to improve. The presence of a substance in the sample tube, which reversed any 
platelet aggregation already present in the sample would be of greatest benefit.
When human platelets aggregate without the release of granule contents deaggregation can be 
readily induced and the fibrin that has been bound during aggregation readily dissociates (Cattaneo 
et al., 1987). The ability of a particular stimulus to induce only primary, reversible aggregation or 
both primary and secondary, irreversible aggregation depends on the species from which the 
platelets are derived, there being variation in sensitivity to various agonists amongst species; and 
the concentration of the agonist. Synergism occurs when platelet stimuli are combined resulting in 
stronger platelet aggregation responses than those observed with the individual stimuli (Adams, 
1985). The particular stimulus or stimuli occurring during blood sampling and sample handling in 
cats is unknown. Thus the possibility exists that aggregation may be reversed in at least some 
samples, especially those in which aggregation is mild.
Deaggregation of platelets which have undergone primary aggregation has been demonstrated in 
human and rabbit platelets (Kinlough-Rathbone et al., 1983), and occurs readily and immediately 
with the addition of EDTA, PGEi or PGI2. The addition of a proteolytic enzyme is required to 
deaggregate human platelets that have undergone secondary aggregation induced by thrombin 
(Kinlough-Rathbone et al., 1985). Collagen aggregated platelets can be deaggregated with PGI2 in 
an in vivo model in the cat (Gryglewski et al., 1978). Theophylline enhances this deaggregatory 
effect (Gryglewski etal., 1978).
Even if aggregation cannot be reversed, prevention of further in vitro aggregation would also be of 
benefit. Several products prevent aggregation of feline platelets if present before the aggregatory 
stimulus occurs (Table 6.1). Platelet inhibitory drugs continue to be developed and investigated for 
use in prevention of human thrombotic disease, but published investigations of their efficacy in 
feline platelets are lacking.
CTAD was chosen for study because it is stable at room temperature, commercially available and 
inexpensive. Although both PGI2 and PGEi have demonstrated efficacy in inhibiting feline platelet 
aggregation (Gryglewski et al., 1978; Hwang, 1985; Welles et al., 1994b), their instability and 
handling requirements makes them unsuitable for clinical use (Welles et al., 1994b; Narayanan,
1995).
Unfortunately the practical application of CTAD is limited by its liquid form and the dilutional errors 
that result from its use. Other anticoagulants which have been recommended to reduce platelet 
activation include a mixture of acid-citrate-dextrose (ACD), aspirin (acetyl salicylic acid) and PGEi 
(Files et al., 1981; Narayanan, 1995), and a mixture of aspirin (acetyl salicylic acid), formaldehyde 
and EDTA (Valli et al., 1980), but both of these are also liquids. A dry anticoagulant containing 
pyridoxal-5'-phosphate (PLP) has been developed for use in human haematology which avoids the
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platelet aggregation induced by EDTA or citrate and is suitable for measurement of routine 
haematological parameters (Lippi etal., 1990). PLP inhibits primary aggregation by ADP, and leads 
to rapid disaggregation of ADP-aggregated rabbit platelets (Lam et al., 1980). Its mechanism of 
action remains unclear but is not the result of increasing cAMP concentrations within the platelet 
(Lam etal., 1980). The PLP containing anticoagulant has not yet been evaluated in feline blood, but 
it warrants further investigation. However, because of the morphological stability of cells in EDTA 
(Tvedten, 1994b), development of an EDTA-based anticoagulant with platelet inhibitory activity may 
have advantages for simultaneous performance of the full blood count. Repeated analysis of 
samples over time is needed to evaluate this.
The methods used in this evaluation of CTAD were simple and demonstrate the clinical application 
of the anticoagulant. However, a more thorough evaluation of the advantages of a particular 
anticoagulant could be made using specific techniques to quantify platelet aggregation. Platelet 
aggregometers measure the size of platelet aggregates by either analysis of light transmission or 
impedance. The size of aggregates is proportional to the extent of platelet aggregation (McNicol,
1996). As aggregation progresses, light transmission through a stirred platelet suspension 
increases and is compared to a control solution (McNicol, 1996). This method is, in general, 
qualitative rather than quantitative (Adams, 1985). The impedance method is more suited to 
comparing platelet aggregation in different anticoagulants as it allows measurement of platelet 
aggregation in whole blood as well as platelet suspensions (McNicol, 1996). Following activation, 
platelet aggregates form on two electrodes placed in the platelet solution impairing the electrical 
conduction (McNicol, 1996). Both methods correlate well with each other (McNicol, 1996), but 
require specific equipment. Other techniques which can be used to quantify secondary (irreversible) 
platelet aggregation include assay of substances released from platelets following granule release 
such as p-thromboglobulin, serotonin, ATP, (3-glucuronidase, and thromboxane A2 (McNicol, 1996). 
These methods cannot be used to quantify the degree of platelet activation or primary, reversible 
aggregation which may occur with a mild stimulus. In addition the plasma separation procedures 
required may further activate platelets.
The activation of platelets, as occurs prior to aggregation, can be detected by several methods. The 
expression of surface antigens on the platelet following activation can be detected using 
monoclonal antibodies that bind only to activated and not to resting platelets (Shattil et al., 1987; 
Michelson and Shattil, 1996). Activation dependent antigens that have been studied include P- 
selectin and anbp3 integrin (glycoprotein llb/llla) (Michelson and Shattil, 1996). Fluorescence- 
conjugated antibodies are detected using flow cytometry and only small volumes of whole blood 
and minimal manipulation of samples is required (Shattil et al., 1987; Welles et al., 1994b; 
Michelson and Shattil, 1996). However, this technique cannot be used to measure the amount of 
fluorescence per individual platelet if the platelets are aggregated (Michelson and Shattil, 1996). 
Exposure of fibrinogen binding sites following activation can be detected using radioactive labelled 
fibrinogen (McNicol, 1996). Likewise this technique cannot be applied to aggregated samples in
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which native fibrinogen is already bound. In density-gradient analysis fractionation of platelets is 
performed by centrifugation in special media, the lowest density platelets being those which have 
undergone the most activation (Zelmanovic and Hetherington, 1998). This process is expensive, 
technically difficult and requires large volumes of blood (Zelmanovic and Hetherington, 1998).
A new platelet parameter, mean platelet component concentration (MPC) is measured by the 
ADVIA® 120 Hematology System (Bayer Corporation, Tarrytown, NY). Using a method of two-angle 
laser light scattering flow cytometry, the refractive index of individual platelets can be determined 
which is related to both platelet density and activation state (Zelmanovic and Hetherington, 1998). 
Thus MPC provides a simple measure of platelet activation state but only in the unaggregated 
platelets within a sample (Zelmanovic and Hetherington, 1998). However in their study of feline 
blood samples, Zelmanovic and Hetherington, (1998) found that in aggregated samples, the 
remaining, free, unaggregated platelets also has an increased MPC, suggesting that they too were 
activated. Unfortunately MPC measurements are only accurate in blood samples collected in EDTA 
(Zelmanovic and Hetherington, 1998). This is because the spherical transformation of platelets in 
EDTA, which does not occur with citrate based anticoagulants, is necessary for application of the 
Mie scattering theory used to analyse the scattering signals (Zelmanovic and Hetherington, 1998). 
Therefore development of an EDTA-based anticoagulant with platelet inhibitory activity may be ideal 
for use with this equipment.
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abbreviations
7. A ppendices
7.1. A bbreviations
ACD................acid-citrate-dextrose
ADP................adenosine diphosphate
AMP................adenosine monophosphate
ATP................adenosine triphosphate
cAMP..............adenosine3\ 5-cyclic monophosphate
cGMP  guanosine 3’, 5-cyclic monophosphate
CHS................Chediak-Higashi syndrome
CPD................citrate-phosphate-dextrose
DDAVP...........desmopressin
DIC.................disseminated intravascular coagulation
DNA................deoxyribonucleic acid
EDRF..............endothelium-derived relaxing factor
EDTA..............ethylenediamine tetra-acetic acid
FDP................fibrin degradation products
FeLV...............feline leukaemia virus
FIP.................. feline infectious peritonitis
FIV.................. feline immunodeficiency virus
G proteins guanine nucleotide-binding proteins
G6PD..............glucose-6- phosphate dehydrogenase
(GM)-CSF granulocyte-macrophage colony stimulating factor
GMP...............guanosine monophosphate
GP..................glycoprotein
GTP................guanosine triphosphate
IL .................. interleukin
K L ..................c-kit ligand
MCV...............mean cell volume (of red cells)
M L..................Mpl ligand
MPV................mean platelet volume
mRNA.............messenger ribonucleic acid
PAF................platelet-activating factor
PCV................packed cell volume
PDGF.............platelet derived growth factor
P F ..................platelet factor
PG..................prostaglandin
PGD2..............prostaglandin D2
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abbreviations
PGI2.................prostacyclin, prostaglandin l2
PRP.................platelet rich plasma
RBC.................red blood cell
SLE..................systemic lupus erythematosis
t-PA .................tissue plasminogen activator
TXA2............... thromboxane A2l thromboxane
vW D............... von Willebrand’s disease
vW f..................von Willebrand’s factor
WBC............... white blood cell
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modified May-GrQnwald-Giemsa stain
7.2. Preparation  of Blood  S mears using  the  Mo dified  Ma y -G runw ald - 
G iem sa  Stain
Preparation of the stain:
A new batch of stain should be prepared every 3-5 days
Buffered distilled water pH 6.8
Buffer tablets pH 6.8: BDH GURR® Prod 33199 *
1 tablet dissolved in distilled water and made up to 1 litre.
May and Grunwald's stain: BDH GURR® Prod 35025S (1 litre).
Freshly diluted to 50% with buffered distilled water and filtered before use.
Giemsa's stain improved R66: BDH GURR® Prod 35086 5P (1 litre).
Freshly diluted to 7.5% with buffered distilled water and filtered before use.
Blood smear staining method:
• Fix air-dried films in methanol for 5 minutes.
• Immerse slides in May-GrQnwald stain for 6 minutes.
• Transfer slides, without washing, into Giemsa stain for 6 minutes.
• Repeat step 3. using separate bath of fresh stain.
• Wash slides in buffered distilled water, rapidly, 3 times.
• Allow slides to stand in buffered distilled water for 1 minute to allow differentiation to take place.
• Stand slides upright to dry.
This is a Romanowsky stain and its properties depend on the interaction of methylene blue, 
methylene blue azure and eosin components. The methylene blue, a basic dye, is taken up by the 
acidic groupings of the nucleic acids and proteins of the cell nuclei and primitive cytoplasm, ie DNA 
and RNA. Basophil granules, contain heparin, which is acidic, also have an affinity for this dye, and 
stain blue. Methylene blue azure stains the azurophil granules of leukocytes. Eosin, which gives a 
red colour, is an acidic dye which reacts with basic groupings e.g. the haemoglobin molecule. The 
granules of eosinophils contain a spermine derivative which reacts strongly with eosin.
BDH Laboratory supplies, Poole, England BH15 1TD, telephone: (01202) 669700
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